

INFORMATION FOR DELEGATES

VENUE

You will find a diagram showing details of the venue inside the back cover of this reader. We hope that this will assist you in navigating your way around the building. Should you have any problems with this, or require any additional information not included here, please ask one of the conference staff or volunteers, or visit the information desk on the ground floor, next to the main entrance.

Please note that the entire building is non-smoking. The only place you can smoke is outside and please use the bins provided to dispose of used smoking materials and other waste.

REGISTRATION AND DELEGATE BADGES

The Registration and Information Desk is located next to the main entrance to the venue in the Dome. Event management staff and volunteers will serve at this desk at the following times:

- ◇ Sunday 3rd April 11:00 to 17:00
- ◇ Monday 4th April 07:30 to 18:00
- ◇ Tuesday 5th April 07:30 to 18:00
- ◇ Wednesday 6th April 07:30 to 18:00
- ◇ Thursday 7th April 07:30 to 16:00

Conference delegates must wear their badges at all times in order to gain access to the conference sessions and exhibition areas, as well as the conference **networking and social events**. Conference volunteers and the venue security will not allow anyone to enter the conference area without a valid badge.

If you have mislaid your badge, please contact Registration Desk. Replacement badges will be issued at a cost of **\$75** each.

CONFERENCE PROGRAMME

Following the Opening Ceremony on Sunday 3rd April the formal programme for the conference will run daily from 09:00 to 17:30 Monday 4th to Wednesday 6th April and from 09:00 to 17:00 on Thursday 7th April. Full details of the programme are contained in a later section of this reader. All abstracts for oral and poster sessions can be found on Conference CD.

LANGUAGES AND TRANSLATION

The official language for IHRA conferences is English. However, in keeping with the conference organisers' commitment to providing simultaneous translation, Harm Reduction 2011 will have simultaneous translation between English and Arabic and English and French for over half of the formal conference programme – including:

- ◇ Opening and Closing Sessions
- ◇ Plenary and Major Sessions
- ◇ half of the Concurrent Sessions (those that are taking place in Banquet Hall 1+2, Banquet Hall 3 and Banquet Hall 4)

In addition all sessions in the main auditorium (Banquet Hall 1+2) will have simultaneous translation between English and Russian.

Translation headsets can be obtained by the entrance to the plenary room. To obtain a headset, delegates are required to deposit a **valid passport, identification card or credit card**, which will be returned in exchange for the headset at the end of each day.

Delegates will be charged **\$200** for lost or misplaced headsets.

In order to avoid large queues for headsets, please think ahead and obtain your headset during the breaks before each session. Please return the headset equipment at the end of each day to ensure they can be recharged for use the following day.

SPEAKERS

All speakers **MUST** upload their presentation slides in the "Speakers Room" at least 12 hours before their session – and **WILL NOT** be able to upload their presentations in the session rooms.

The "Speakers Room" is located in the Habtoor Hotel Business Centre, floor 1 and it will be open as follows:

- ◇ Sunday 3rd April – 13:00 to 16:00
- ◇ Monday 4th April – 08:00 to 17:00
- ◇ Tuesday 5th April – 08:00 to 17:00
- ◇ Wednesday 6th April – 08:00 to 17:00
- ◇ Thursday 7th April – 08:00 to 11:00

MTV INTERNATIONAL DRUGS AND HARM REDUCTION FILM FESTIVAL 2011

Film presentations and screenings will take place on the 3rd floor in Room Beirut. Please see the separate "Film Festival Programme" for further information.

POSTERS

Posters will be exhibited in the main auditorium (Banquet Hall 1+2) There will be 3 poster sessions: Session 1: Monday 4th, Session 2: Tuesday 5th and Session 3: Wednesday 6th with different posters displayed during each. Change of display will take place each day in the morning, before first plenary session or afternoon after last plenary session.

The prime time for viewing will be during coffee and lunch breaks and we would ask that all those exhibiting their work try to be available at least during these times to answer any questions delegates might have about their exhibits.

EXHIBITION AREA, DIALOGUE SPACE AND HARM REDUCTION DEMONSTRATION AREA

This is located on level – 1 in Lobby 1 (Dome Side) and Lobby 2 (Hotel Side). The exhibitors are key supporters of the IHRA conferences and we encourage all delegates to take the time to explore the numerous display stands. The area also hosts the dialogue space – a recent addition to the conferences – where there will be a programme of more "informal" presentations, discussions and debates taking place throughout the conference. More information about these sessions will be found in the Dialogue, Debate and Workshop guide distributed in the delegate bags.

WORKSHOPS AND TRAININGS

A full programme of Workshops and Trainings will take place in the Jamhour Room, on level 3 of the Convention Centre. Places are limited! Sign up early: Workshop and Training sessions are limited to strictly 25 people. Sign up for Workshops and Trainings is at the IHRA booth in the Dome on Sunday and Monday morning, and thereafter outside the Workshop room. Details will be found in the Dialogue, Debate and Workshop guide.

LUNCH AND REFRESHMENTS

From Monday 4th to Thursday 7th April morning coffee, lunch and afternoon tea will be served in the exhibition area in both Lobby 1 (Dome Side) and Lobby 2 (Hotel Side). To enter the exhibition area all delegates must display a valid delegate badge.

Serving times for lunch and refreshments are:

- ◇ Morning coffee 10:30 to 11:00
- ◇ Lunch 12:30 to 14:00 (Thursday 7th April 12:30 to 13:30)
- ◇ Afternoon tea 15:30 to 16:00 (from Monday 4th to Wednesday 6th)

WELCOME RECEPTION

All delegates are invited to the welcome reception, which takes place on Sunday 3rd April from 18:30 to 20:00, in the exhibition area. This is an opportunity to meet other delegates, renew old acquaintances and make new ones, in an informal atmosphere. There will be a complimentary drink and canapés provided. There will be a number of other meetings, social and networking opportunities during the conference and you should see the daily bulletins, distributed each morning for further details.

MEDICAL AND HARM REDUCTION SERVICES

In addition to general first aid services provided by staff from the venue, there will be some specialist medical, health care and harm reduction facilities coordinated by Gill Bradbury – Registered General Nurse – and her assistants, who are also experienced harm reduction practitioners. They will be available, for individual consultation, in the designated medical room (access from Lobby 2, Hotel Side) during conference hours. They will conduct a brief triage assessment to establish which external services you require referral to, and will make the necessary arrangements for you to attend and receive treatment there. No prescribing services will be available

on site and acute / primary health care needs will be met by a local General Practitioner (doctor) following triage assessment.

MEDIA

All media and press matters are handled by Michael Kessler, IHRA's media consultant, who can be contacted in Media Room, located in the Habtoor Hotel Business Center, floor 1.

Mobile: +961 719 52635

Email: mkessler@ya.com

Skype: mickgpi

PROGRAMME**Sunday 3rd April 2011****16:20****OPENING SESSION****Banquet Hall 1+2**

Chair: Rick Lines

OS**Opening of Harm Reduction 2011: IHRA's 22nd International Conference****Welcome addresses****Rick Lines**

Executive Director, International Harm Reduction Association

Elie Aaraj

SIDC and Middle East and North Africa Harm Reduction Association (MENAHRRA)

Nabil Kahalah

President of the Municipality of Sin el Fil

Jude Byrne

Chair of International Network of People who use Drugs (INPUD)

Anita Krug

Coordinator of Youth RISE

International Rolleston Award – presentation**Keynote conference address****Joanne Csete, *Intersecting inequities: in search of drug policy justice***

Columbia University Mailman School of Public Health, New York, USA

Georges Kordahi

Film Festival trailer

Hussein Gezairy

Regional Director, World Health Organization, Eastern Mediterranean Regional Office

Mohamad Jawad Khalifeh

Minister for Health, Lebanon

18:45**WELCOME RECEPTION FOR ALL DELEGATES**

All delegates are invited to the welcome reception, which takes place on Sunday 3rd April from 18:30 to 20:00, in the exhibition area.

Monday 4th April 2011

09:00–10:30
PLENARY SESSION
Banquet Hall 1+2
Chair: Rick Lines

P1
Building capacity
Kasia Malinowska-Sempruch
1161 What does it take to reform drugs policy? Are we there yet?

Judith Byrne
1156 From famine to feast – well at least a seat at the table!

Nafsiah Mboi
1162 The experience of implementing harm reduction in Indonesia

Elie Aaraj
1163 Evolving Harm Reduction Strategy in MENA Region: the experience of MENAHRA

10:30–11:00
TEA/COFFEE BREAK
11:00–12:30
MAJORS
Banquet Hall 1+2
M01
Chair: Vitaly Zhumagaliev

Global examples of innovative advocacy
Nadya Mikdashi
599 Lobbying for national policies: a lesson in diligence and collaboration

Pierre Chappard
952 France: a mock supervised injection facility as a step forward for harm reduction

Konstantin Lyezhentsev
423 Launching price reduction dialogue to ensure access to life-saving HCV treatment

Violet Fasheh
428 Harm reduction advocacy campaign

Larisa Pintilei
286 Moldova shows the way: influencing changes in national policy on harm reduction programs in Moldovan prisons

Banquet Hall 3
M02
Chair: Annette Verster

Highlights in harm reduction research
Dan Ciccarone
687 Rising tide: trends in heroin price, purity and heroin related consequences in the US: 1990–2008

Gregory Scott
1031 An ethno-geographic visual study of injection-related risk behavior complexity

Bradley Mathers
690 Triangulating data from global collection systems – improving our understand of the global response to HIV among IDUs

Tim Rhodes
439 Discipline and delay: access to treatments for HIV, tuberculosis and drug use in a Russian city

Banquet Hall 4
M03
Chair: Judith Byrne

Drug users speak: perspectives from around the globe
James Rowe
176 Using personal experience to undermine prejudice: the junkie university lecturer

Rawya El Chab
1155 The voice of drug users of Lebanon

Olga Byelyayeva
323 You should be HIV-infected to receive methadone?

Dayle Stubbs
979 Injecting drugs: it's time to talk about pleasure

12:30–14:00
LUNCH BREAK

PLENARY ABSTRACTS

1161 What does it take to reform drugs policy? Are we there yet? P1

2011 marks the 50th anniversary of the United Nations Single Convention on Narcotic Drugs, the 40th anniversary of President Nixon's War on Drugs, and the 10th anniversary of the UNGASS Declaration of Commitment on HIV/AIDS. The world has borne witness for half a century to the failures of the current global drug policy regime. Change is needed and the number of advocates for more humane drug policies is growing. The 2010 Vienna Declaration has gathered 20,000 signatures in support of drug policy based on science. In July 2010, The Lancet published a special issue on HIV among drug users. Three former Latin American presidents from Brazil, Mexico and Colombia in 2009 established the Latin American Commission on Drugs and Democracy and called for alternatives to the current regime. A Global Commission on Drugs Policy that will aim for highest level impact is now in deliberation. Economists are counting the costs of failed drug policies, human rights activists are documenting human rights abuses, physicians are advocating for the rights of their patients. There are more voices calling out for a more rational global drugs policy, voices that are both numerous and varied. As the AIDS movement has shown, by providing HIV medicines to people in the South, it is possible to dramatically shift attitudes and policies and to secure funding. It also shows that it is impossible to achieve this turnaround without a strong and diverse support base. Drawing on the experience of 50 organisations that are partnering with the Global Drug Policy programme, Open Society Foundations, this presentation will look at what is being done to advocate drug policy reform and propose how to identify capacity gaps that require urgent attention.

1156 From famine to feast – well at least a seat at the table! P1

It is a time of much hope and anticipation in the drug using community, especially in the international arena. After many years of feeling we would never break through the barriers that prevented us from working with other organisations and governments we finally feel our skills are being acknowledged. Partnering with other organisations we can and are providing the most effective and efficient programmes to our community. We have finally been recognised as having the technical skills and practical know-how that ensures that working with our community is a successful and positive experi-

ence for all involved. I will not dwell on the fact that it has taken over twenty years for drug users' representative organisations to be provided with the same recognition that other health or welfare related consumers groups were afforded. I will not discuss the structural violence, the social stigma and the discrimination that is played out on a day-to-day basis that makes our work so much more difficult. I will instead talk about the achievements of the International Network of People who use drugs (INPUD) over the past 18 months in the face of those extraordinary challenges. I will talk about the changes that have occurred in both a philosophical sense and practical sense within the harm reduction community that have made many of the barriers come down. I will talk about how you, as individuals and organisations, have assisted in these monumental changes and the ways that you can further engage with INPUD and its community to realise its goal of being a voice on the global stage for our regional and local communities. This will ensure that their voices are being heard and they are not being intentionally or unintentionally "neglected".

1162 The experience of implementing harm reduction in Indonesia P1

By 2006, unsafe drug injecting contributed a significant proportion (48–50%) of reported HIV infections in Indonesia, the world's fourth most populous country. Indonesia's response was hampered by laws criminalising the carrying of needles and syringes and controlled substances and the resistance of some in government to change existing regulations and attitudes toward the injecting of drugs. Nonetheless, harm reduction started in 1997 in scattered locations on a modest scale by Indonesian NGOs using external funding and some technical support. With reorganisation, strengthening, and energising of the National AIDS Commission by Presidential decree 75/2006, systematic efforts were undertaken in partnership with civil society and networks of people who inject drugs (PWID) to expand harm reduction efforts and to intensify advocacy for policy, legal, and programmatic reform needed for legalisation and major scale-up of services in public health and prison systems. In 2005 harm reduction was found in only four provinces. By 2009, 281 NSPs and 54 OST were established in 16 provinces. In 2009 a new drug law recognised the human rights of PWIDs including the right to treatment, rehabilitation and protection from prosecution for drug use. Reported new HIV infection among PWIDs declined from 1517 (2006) to 1156

(2009); HIV prevalence among PWIDs decreased from 48%–50% (2006) to 39%–42% (2009). Indonesia has demonstrated the importance of using an evidence-informed and comprehensive approach to advocacy, the crucial role of civil society and PWIDs empowered with information and working in partnership with government bodies. Harm reduction is making a major contribution to bringing Indonesia's HIV epidemic under control.

1163 Evolving Harm Reduction Strategy in MENA Region: the experience of MENAHRA P1

Middle East and North Africa (MENA) is experiencing emerging HIV epidemics among IDU. Afghanistan, Pakistan, Iran, Libya, Bahrain and Egypt have concentrated HIV epidemics among IDU. Oman and Morocco have signs of similar epidemics, yet to be confirmed with surveillance studies. Hepatitis C prevalence rates among IDU ranging from 45–93% in Lebanon, Palestinian territories, and Iran. Middle East and North Africa Harm Reduction Association (MENAHRA) has conducted a desk review on IDU, HIV, harm reduction in MENA as part of a baseline assessment. MENAHRA's advocacy, training and technical assistance activities were monitored and evaluated to observe change over time. In 2008, only Iran had a comprehensive harm reduction program with acceptable coverage. Other countries had limited scale interventions often bound to outreach with or without syringe distribution. Drug treatment was limited to detoxification and rehabilitation, often falling short of the need for the service. Civil society involvement was very limited in most countries. Harm reduction policies were not adopted, but considered in Morocco, Lebanon and Afghanistan. Very limited resources were allocated or mobilized for harm reduction interventions. By the end of 2010, OST has been introduced in Morocco, Afghanistan and Lebanon. Pakistan has mobilised resources for introducing OST and scaling up other harm reduction services. Tunisia and Syria attempted mobilising resources for harm reduction from the Global Fund (GF). Oman initiated actions for introducing OST and Bahrain requested MENAHRA's assistance to explore possibilities. MENAHRA mobilised substantial resources for harm reduction from the Global Fund. There had been an increased acceptance of harm reduction in MENA. It is difficult to assess the contribution of MENAHRA to this change however; MENAHRA's M&E show a significant role in inducing this change. It is imperative to keep up the advocacy and the capacity building efforts in MENA.

Monday 4th April 2011

14:00–15:30

Banquet Hall 1+2

C01

Chair: Ingrid van Beek

Harm reduction developments in Middle East and North Africa

Gordon Mortimore

270 Social marketing of safe injecting kits in Kabul, Afghanistan

Amina Latifi

1000 Psychological and social support as essential components of HIV care for injecting drug users living with HIV

Shabnam Salimi

1148 A women's drug clinic in Iran: improvements in drug use, social functioning and low HIV/HCV seroincidence.

Ghina Mumtaz

1151 The status of the HIV epidemic among injecting drug users in the Middle East and North Africa

Banquet Hall 3

C02

Chair: Pablo Cymerman

Monitoring and evaluating approaches in harm reduction

Joumana Hermez

775 A monitoring and evaluation system for harm reduction services in the MENA region

Danielle Horyniak

656 Behavioural interventions for preventing hepatitis C infection in injecting drug users – a systematic review and meta-analysis

Ahmad Hadjebi

992 Effectiveness of adding a brief skill-based HIV prevention psychoeducation to needle syringe programs: a randomized controlled trial

Claude Jeanrenaud

857 How effective is smoking prevention in Switzerland?

Banquet Hall 4

C03

Chair: Jeffrey Lazarus

Advocating for drug policy reform in Central Europe

Agnieszka Sieniawska

884 Report of the ombudsman for addicts and drug users program – good practice from Poland

Vendula Belackova

746 Rational drug policy in central Europe

Tatiana Hicarova

602 For how long the evidence can be neglected?

Fear driven drug legislation in Slovakia

Simona Merkinaitė

1057 European harm reductionists and HIV community unite to bring about evidence-based drug policies in the EU and neighbouring countries

Session supported by Global Drug Policy program, OSF

15:30–16:00

16:00–17:30

Banquet Hall 1+2

C06

Chair: Kasia Malinowska-Sempruch

International drug policy campaigns

Dan Werb

876 The Vienna Declaration: building international consensus in support of drug policy reform

Rupert George

868 Messaging for a global audience: talking drugs – talking reform

Meghan Ralston

437 Using Twitter to raise international awareness about overdose on international overdose awareness day: a zero-cost, effective overdose awareness campaign

Peter Sarosi

1065 Dare to act: a campaign against the global war on drugs

Session supported by Global Drug Policy program, OSF

Banquet Hall 3

C07

Chair: Emran Razaghi

Epidemiology and surveillance of drug harms

Brendan Quinn

643 Incarceration and its correlates in an Australian cohort of community-recruited people who inject drugs

Adnan Khan

466 Social factors determine HIV infections as much as drug factor among IDUs in Karachi

Ritu Mishra

390 Risk behaviours among injecting drug users in North-East India: findings from polling booth surveys

Frederick Altice

893 Structural factors influencing morbidity and HIV treatment engagement among injection drug users in the Klang Valley, Malaysia

Banquet Hall 4

C08

Chair: Mick Matthews

Community development

Raffi Balian

807 Meaningfully driven

Nicolette Burrows

1073 Building regional solidarity between Australasian sex worker and drug user organisations

Mohammad Abdur

1088 Promoting community development – a key component of an effective harm reduction strategy at the epicentre of the war on drugs

Bishnu Sharma

883 Policy change by meaningful involvement

13:00–17:00

DIALOGUE SPACE

13:00–13:30

Introducing MENAHRA's new Global Fund grant

13:30–14:30

Change we can believe in? The inside story of PEPFAR and US politics on drug policy

14:30–15:00

Book launch – Harm Reduction at Work

15:00–15:30

Introduction to drug user organising

15:30–16:00

Youth friendly resources

16:00–16:30

The roll back of harm reduction in Europe?

16:30–17:00

"Harm Reduction" and the "New Recovery": time to evolve a more integrated approach?

For further details on the dialogue space sessions please refer to the *Dialogue, Debate and Workshops* handout.

AFTERNOON

CONCURRENT SESSIONS

Rabieh **C04**
Chair: Carolyn McDonald
Services for women
Wendy Muckle
525 Harm reduction and integrated care: an evaluation of the special care unit for women in Ottawa
Yunnam Singh
686 Delivering gender-sensitive services for female injecting drug users in Manipur
Irina Maslova
1017 Experience in case-management for pregnant IDUs in St. Petersburg, Russia
Chhen Reksmey
745 Meeting the needs of female drug users in Cambodia

Hamra **C05**
Chair: John Hedge
Reducing alcohol-related harm
Hom Lal Shrestha
243 Alcohol policy in Nepal: a harm reduction strategy
Robert Power
261 Alcohol related violence: a real but as yet undefined obstacle to development in the Pacific region
Bangorn Sirojrn
455 Alcohol drinking environment and sexual risk among underage young Thai
Sanji Gunasekara
597 Trade liberalisation can worsen the harms from tobacco and alcohol

WORKSHOPS

11:00–12:30
 Setting up a nationwide programme on opioid substitution treatment (OST)
12:45–14:15
 Peer Support Work: meaningful co-operations between communities, services and policy makers
14:30–16:00
 Overdose prevention training
16:10–17:40
 Challenges to the adoption of harm reduction policies

For further details on the workshops sessions please refer to the *Dialogue, Debate and Workshops* handout.

TEA/COFFEE BREAK

CONCURRENT SESSIONS

Rabieh **C09**
Chair: Javier Rio Navarro
Safe injecting facilities and their community acceptance
Patricia Allard
806 Political maze: the survival of supervised injection sites in Canada
Astrid Leicht
503 Innovative approaches for preventing infection with hepatitis C among drug users
Robert Haemmig
1003 25 years of safe injecting facilities and 15 years of heroin-assisted treatment as a regular treatment option in Switzerland: present state and future directions
Ian McPhail Flaherty
1149 Media portrayal, community perceptions and trends in prescription opioid injecting of the Sydney Medically Supervised Injecting Centre, 2001–2010

Hamra **C10**
Chair: Murtaza Majeed
Young people in search of evidence
Patricia Haddad
564 Why I did drugs: a glimpse into the life of young Lebanese drug users
Brun González
662 Young people, drugs and risky sexual behaviors in Latin America: reducing harm among non-injectable drug users
Maria Phelan
839 Excluded and ignored: the gaps and failings in research on youth drug use and the implications for harm reduction
John Howard
159 "Opening Doors" – delivering youth friendly harm reduction in Asia

DEMONSTRATION AREA

10:30–11:00
 Tobacco harm reduction
12:30–13:00
 Crack cocaine harm reduction
13:00–13:30
 Overdose response
13:30–14:00
 Needles and syringes
15:30–16:00
 Female condoms

For further details on the demonstration area sessions please refer to the *Dialogue, Debate and Workshops* handout.

12:30–17:35

FILM FESTIVAL

LUNCHTIME 12:30–14:00

12:30 Welcome to the Film festival
12:42 Shaken and Slurred (UK)
12:45 Howard Marks on Drugs (UK)
13:45 Russia and Methadone: Breaking the Ice (Hungary)

SYMPOSIUM 14:00–15:30¹

14:00 Forward Step (Kyrgyzstan)
14:20 Abuse in the name of treatment: Drug Detention Centres in Asia (Hungary)
14:42 REUNI PUTIH (Indonesia)
15:10 In the midst of life – former drug users and people on substitution treatment in working life (Germany)

LOUNGE 15:45–18:00

15:45 La Liga (Spain)
16:15 AIDS on the Heroin Trail (Central Asia)
16:40 Rig Dig (Canada)
16:50 The Adventures of Methadone Man and Buprenorphine Babe (USA)
17:05 Harm Reduction in Sao Paulo (Brazil)
17:35 Pappu Park (India)

¹) Timings for symposium sessions include running time of film plus 10 mins speaking time

Tuesday 5th April 2011

09:00–10:30
PLENARY SESSION
Banquet Hall 1+2
Chair: Christian Kroll

P2
Neglected issues
Bronwyn Myers
1164 A global review of the risks and services needs of women who inject drugs

Aram Barra
1165 Young people leading the drug policy revolutions

Haileyesus Getahun Gebre
1159 TB among injecting drug users: urgent action needed to address the neglect

Pye Jakobsson
1157 Hard-to-reach communities – who do we mean and why do we talk about them?

10:30–11:00
TEA/COFFEE BREAK
11:00–12:30
MAJORS
Banquet Hall 1+2
M04
Chair: Anne Coppel

Building a women-centred harm reduction response
Sophie Pinkham
578 Building partnerships and overcoming stereotypes to respond to the needs of women who use drugs

Katya Burns
777 Women-centred harm reduction programming in resource constrained settings

Jennifer Kelsall
882 The (secret social) history of female drug users

Ruth Birgin
158 The women's harm reduction movement

Banquet Hall 3
M05
Chair: Chantale Kallas

Young people want better drug policies. Don't you?

This session is a panel discussion and will not include full presentations. Participants will discuss drug policies, harm reduction services and young people.

Lynn Itani, Youth Rise, *Lebanon*
Anita Krug, Youth Rise, *Sweden*
Rick Lines, IHRA, *United Kingdom*
Banquet Hall 4
M06
Chair: Alvaro Bermejo

Developing harm reduction interventions in prisons in Middle East and North Africa
Atef Sherif
492 The Egyptian experience in drug-use and HIV prevention within prison settings

Fatima Asouab
600 HIV prevention and reducing negative health consequences of drug use in prisons in Morocco

Bahman Ebrahimi
1154 Developing harm reduction interventions in prisons

Fabienne Hariga
498 UNODC global programme on HIV prevention, care, treatment and support in prison settings

12:30–14:00
LUNCH BREAK

PLENARY ABSTRACTS

1164 A global review of the risks and services needs of women who inject drugs **P2**

Women are often ignored in discussions about people who inject drugs. From the evidence available in many parts of the world, women appear to comprise only a small proportion of people who inject drugs, yet evidence suggests that women face more risks and experience greater harms than male injectors. Women injectors also face more barriers to services than their male counterparts, which further entrenches their vulnerability to drug-related harms. This presentation provides a global perspective on injecting drug use among women by providing an overview of the;

- prevalence of injecting among women,
- the risks for women associated with injecting drugs, and
- the service needs for women who inject.

The presentation is based on an analysis of global data injecting drug use and HIV maintained by the International Reference Group to the United Nations on Injecting Drug Use and HIV, as well as systematic literature reviews.

1165 Young people leading the drug policy revolutions **P2**

For too long, young people have been the subject of drugs policies without any real assessment of the impacts of these initiatives on young people or without significantly taking into account the opinions and needs of the community. From the 12 year old boy that shoots up heroin in the Ukraine, to the young indigenous coca leaf grower in Bolivia, or the 16 year old ketamine user at dance clubs in Europe, young people are involved in

both the demand and supply of drugs. We are active in prevention, harm reduction and treatment responses and are relevant actors in making decisions regarding the policies that affect our own lives. However, we continue to be a neglected population worldwide. This presentation will tackle some of the most relevant cases and best practices of young people leading the drug policy revolutions from national, regional and international perspectives, and concerning judicial, service provision and advocacy frameworks.

1159 TB among people who inject drugs: urgent action needed to address the neglect **P2**

People living with HIV have a 20–40 fold increased risk of developing TB disease as compared to people without HIV. Similarly, people using drugs have a higher risk of TB including multidrug and extensively drug-resistant TB, irrespective of their HIV status. Furthermore, co-morbidities with viral hepatitis infection are also common. WHO, UNODC and UNAIDS have, since 2008, developed policy guidelines for collaborative TB and HIV services for people who inject and other drug users through an integrated approach. The guidelines define the package of key TB prevention, diagnosis and treatment interventions that need to be provided for drug users living with HIV. However, the implementation of the recommendations of these guidelines particularly in countries where injecting drug use is fuelling the TB epidemic has almost been non-existent. The presentation will highlight the key progress and challenges around the delivery of integrated TB and HIV services as part of harm reduction for people who use drugs and live with HIV. Successful examples of integrated service delivery will be pre-

sented. Key actions that need to be carried out to scale up the provision of these services by governments, civil society and other stakeholders will be shared and research gaps will be identified.

1157 "Hard to reach communities" – who do we mean and why do we talk about them? **P2**

Service providers often express concerns and frustrations regarding working with so-called "hard to reach" groups. People are seen as being especially "hard to reach" if they belong to more than one marginalised group, for example sex workers who use drugs. After working with indoor sex workers for many years my experience is quite different. Most people want to be reached, most people need some services and everybody wants to be seen by someone. But very often services are set up without proper needs assessment, peer involvement or tools for evaluation. The assumption that certain groups are "hard to reach" is used as an excuse to not try any further. So we have a situation with lots of inadequate services and lots of people who are never reached by them, wrongly assuming they don't want to be reached. After doing needs assessment among sex workers, as well as being one myself, the problem is more often about who, why and how. Who is asking questions? Why is a service provided? And how are we trying to reach people? I've met many sex workers who have never been reached, others that avoid services because of the "wrong" people asking the "wrong" questions. This presentation will provide some thoughts and tools on how to get better at reaching people. Like a colleague of mine said "I want to have access to services, but as long as they are not listening, I'm not buying what they are selling".

Tuesday 5th April 2011

14:00–15:30

Banquet Hall 1+2

Chair: Yasmin Batliwala

Sex work – the police, policies and the law

Jenn Clamen

933 Challenging prostitution laws as a strategy for safer working conditions for sex workers

Thomas Odhiambo Abol

670 Collaborative documentation: a model of sex worker – police cooperation in Kenya

Melissa Ditmore

788 Sacrificing harm reduction practice to moral ideology: the example of the USAID anti-prostitution pledge

Anna-Louise Crago

1094 “Then more died...”: the impact of HIV on the sex worker community in Zambia (1993-2008)

C11

Banquet Hall 3

Chair: Aram Barra

Youth Drug Policy

Chantale Kallas

579 Drug policy impact on young women in the Middle East

Adeolu Ogunrombi

188 Drug policy in African countries: a concern for young people

Nikhil Gurung

1002 Young IDU in South Asia: a situation assessment

Lisa Sánchez Ortega

973 Firing the debate: young people managing sex and drugs in Latin America

C12

Banquet Hall 4

Chair: Alex Wodak

Harm reduction in prison: the role of advocacy

Veronica Noseda

1037 An example of mobilisation in favour of needle exchange programmes in prisons

Jack Wallace

222 Oil and water: regulating hepatitis C prevention in Australian prisons

Agata Kwiatkowska

528 Polish prisons: improving access to substitution treatment – reality, quality, challenges – an advocacy project

Sandra Ka Hon Chu

591 Safe sharp cell: making the case for prison-based needle and syringe programs in Canada

C13

15:30–16:00

16:00–17:30

Banquet Hall 1+2

Chair: Katya Burns

Reducing harm for women: policies and ethics

Lynn Paltrow

574 Pregnant drug using women: policies that promote safe motherhood and child well-being

Astrid Renland

844 When purchase of sex is a crime: a new legal measure and its impact on harm reduction among sex workers in Sweden and Norway

Sian Maseko

446 Doing harm not good: unintended consequences of well-intentioned policies

Amy Salmon

443 Risks, rights, and evidence: promoting ethical and respectful research with and for women who use drugs

C16

Banquet Hall 3

Chair: Susie McLean

Reflections on the methods and practices of harm reduction

Priya Mannava

635 Addicted to development: the relationship of illicit drugs and socioeconomic development

Katherine McLean

220 Rethinking “evidence”: social science and the demedicalization of harm reduction

Richard Elovich

1091 Donor expectations, drug user expectations and harm reduction missions: negotiating tensions between systems and life worlds

Miriam Boeri

581 Social recovery (not recovery capital): an innovative application of social capital for harm reduction initiatives

C17

Banquet Hall 4

Chair: Patricia Allard

Law enforcement and harm reduction

Aliya Rakhmetova

744 Arrest the violence: police abuse of sex workers in Central and Eastern Europe and positive models for intervention

Aibek Mukambetov

895 A matter of fact: collecting evidence of police interference with HIV/AIDS prevention activities in Kyrgyzstan

Leonardo Nogueira

866 Reducing harm: innovative policing in Brazil

Supheap Leang

853 What impact do harm reduction programs have on law enforcement policy and practices to reduce HIV-related risk among drug users and their communities in Cambodia?

C18

12:30–17:00

DIALOGUE SPACE

12:30–13:30

Same, Same... but Different? Are we doing the same things over and over again and expecting a different result?

13:30–14:00

Equity, human rights and the Global Fund

14:00–14:30

Advocating for harm reduction: the role of civil society advocacy networks

14:30–15:00

Book launch – women specific harm reduction materials

15:00–15:30

Meet the drug user activists

15:30–16:00

Advocacy opportunities 2011 and beyond

16:00–17:00

Harm reduction in Eurasia: what are regional advocacy priorities?

AFTERNOON

CONCURRENT SESSIONS

Rabieh **C14**
Chair: Raffi Balian

Stimulants and harm reduction

Kate Smith
924 The effectiveness of harm reduction programs to prevent HIV and HCV transmission among people who smoke crack: a systematic review of the evidence 1990–2008

Eva Rocillo Arechaga
828 Is crack cocaine consumption associated with experience of sexual violence in Honduras?

Ray Stephens
637 Break the Ice – tackling amphetamine related harms locally

Sara Jafari
1153 How to address methamphetamine involvement in OST settings

Hamra **C15**
Chair: Ronnie Waikhom

Reducing drug harms in South-East Asia

Gary Reid
210 People who inject drugs in South-East Asia: situation assessment and the need to accelerate the harm reduction response

Huynh Thi Nguyen
519 Creating positive environment for harm reduction program in three provinces in Vietnam

Hongyun Fu
632 Evaluating the impact of a peer-led approach to IDU harm reduction in Yunnan, China

Dave Burrows
328 Using multiple approaches to assess current IDU projects funded by US government in southern China for possible replication by government of China

TEA/COFFEE BREAK

WORKSHOPS

11:00–12:30
 How to set up a vocational training program for in-treatment drug users

12:45–14:15
 How to implement harm reduction in prisons

14:30–16:00
 Hepatitis C treatment and care: A participative training resource for developing and improving services

16:10–17:40
 Establishing a low-threshold community based opioid substitution treatment programme

For further details on the workshops sessions please refer to the *Dialogue, Debate and Workshops* handout.

CONCURRENT SESSIONS

Rabieh **C19**
Chair: Anna Shapoval

Addressing gaps in prison health: harm reduction, TB and women

Olivier Maguet
255 Adherence to national and WHO harm reduction recommendations in french prisons: a dramatic gap between guidelines and reality

Anya Sarang
318 Prisons as a source of tuberculosis: findings from qualitative research in a Russian city

Hamza Omer
363 Prevalence and risk factors of pulmonary tuberculosis among prison inmates in Khartoum, Sudan

Amalah Rahmah
474 Forgotten women: a qualitative study of reproductive health and HIV risk in 7 women's prisons in Indonesia

Hamra **C20**
Chair: Thierry Schaffauser

Sexual identities and drugs

Daniel Castellanos
1061 Challenges of integrating substance use services in housing programs for homeless LGBT youth

Anthony Rizk
1137 Lesbian, bisexual and queer women and health in Lebanon

Nguyen Van Hai
1038 The results of using IDU RAR methodology to link unknown MSM networks to a provincial AIDS center in a provincial city in northern Viet Nam

Angela Matheson
1150 Recognising difference, building capacity: meeting the needs of lesbians in New South Wales, Australia, who use drugs

DEMONSTRATION AREA

10:30–11:00
 Female condoms

12:30–13:00
 Overdose response

13:00–13:30
 Crack cocaine harm reduction

13:30–14:00
 Tobacco harm reduction

15:30–16:00
 Needles and syringes

For further details on the demonstration area sessions please refer to the *Dialogue, Debate and Workshops* handout.

12:30–17:42

LUNCHTIME 12:30–14:00

12:30 Bamboozled (UK)
12:35 I'm Dangerous With Love (USA)

SYMPOSIUM 14:00–15:30¹

14:00 "LIVE!" Using injectable naloxone to reverse opiate overdose (USA)
14:24 Project Lazarus (USA)
14:55 A light in the dark (Russia)
15:10 Drogues: VIH et autres risques (France)

LOUNGE 15:45–18:00

15:45 Health and Hope Part 2: "Taking Care of Yourself and Your Hepatitis C" (USA)
16:00 John and Lacey's Story (series of 3 short films: Circles, Between Us, Homes) (Canada)
16:18 Sunlight and Shadows (India)
16:30 Forget me not (Nepal)
16:55 Living Juárez: Collateral damage in Mexico's Drug War (Mexico)

FILM FESTIVAL

17:17 Your Shout – an honest discussion about alcohol by young people for young people (Australia)
17:42 Confrontation (Bosnia)

¹Timings for symposium sessions include running time of film plus 10 mins speaking time

Wednesday 6th April 2011

09:00–10:30
MAJORS
Banquet Hall 1+2
M07
Chair: Robert Carr
Sex work – challenges in peer involvement and harm reduction
Fred Chabot
379 To serve and protect? Ottawa area sex workers speak out

Maysa Kassabry
985 Sex workers in Palestine

Borche Bozhinov
774 Legal challenges in registering an association of sex workers in Macedonia

Sandy Guillaume
934 State of sex workers' health and rights in the United States: the barriers to harm reduction and adequate health care

Banquet Hall 3
M08
Chair: Gerry Stimson
Tobacco
Catherine Nissen
917 The Framework Convention on Tobacco Control in the developing world: Western imperialism and the rejection of harm reduction

Karl Lund
1039 Will availability to Swedish type smokeless tobacco (snus) speed up quit-rates for cigarette smoking? Empirical findings from Norway and Sweden

Christopher Snowdon
931 The European Union ban on snus: a costly mistake

Delon Human
716 The value of nicotine in tobacco harm reduction

Banquet Hall 4
M09
Chair: Eduardo Nierras
Barriers to treatment access and how to respond to them
Christine Tapp
927 Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare

Sergiy Filippovych
702 Assessment of integrated care models of medication assisted treatment provision to HIV-positive IDUs within projects supported by USAID in Ukraine

Senop Tschakarjan
1050 Implementing comprehensive case management in opioid substitution therapy in Kabul, Afghanistan

Aung Yu Naing
550 It's the negligence, do not blame the drugs!

10:30–11:00
TEA/COFFEE BREAK
11:00–12:30
MAJORS
Banquet Hall 1+2
M10
Chair: Raminta Stuikyte
Impacts of Global Fund investments in harm reduction: building capacity and promoting change
Ade Fakoya
361 Global Fund Investments in harm reduction: latest data analyses and trends

Liliana Gherman
695 The impact of the Global Fund in Moldova: achieving universal access for injecting drug users?

Fony Silvanus
840 The contribution of Global Fund support to comprehensive HIV prevention and treatment among injecting drug users in Indonesia

Pavlo Smyrnov
1077 Successes in the HIV/AIDS response in Ukraine

Session supported by the Global Fund
Banquet Hall 3
M11
Chair: Stephane Ibanez-de-Benito
Responding to hepatitis B and C
Annie Madden
166 Structural inequalities and hepatitis C

Annette Verster
722 Developing WHO guidance on viral hepatitis B and C for people who use drugs

Eberhard Schatz
194 Key messages for a successful hepatitis C policy, prevention care and treatment

Antoine Abou Rached
575 A country response to viral hepatitis: Lebanon's National Hepatitis Programme

Banquet Hall 4
M12
Chair: Jallal Toufiq
Country experiences in opioid substitution treatment
Jing Wang
684 Building the capacity of drug users to educate and support other drug users about methadone in china

Gregory Armstrong
341 Opioid substitution therapy in Manipur and Nagaland, north-east India: operational research in action

Amin Zemaray
919 Piloting opiate substitution therapy in the Islamic Republic of Afghanistan – first results

Mohammed Essalhi
608 Methadone maintenance program in Morocco: a choice for a mixed implementation, ambulatory facility with harm reduction interventions and detoxification inpatient services

12:30–14:00
LUNCH BREAK

PRESENTATION ABSTRACTS FOR THURSDAY PLENARY SESSIONS – PLEASE SEE PAGE 23

PLENARY ABSTRACTS

1166 Effectiveness and cost-effectiveness of harm reduction P3

Injecting drug use remains a major driver of HIV infection globally and also contributes to the transmission of other BBVs. Although proven, effective harm reduction approaches, including needle-syringe programmes and medication assisted therapy exist, many countries continue to pursue ineffective approaches that are not founded on evidence. In order to promote evidence-based harm reduction approaches, it is essential to present evidence that harm reduction is (a) effective and (b) cost effective.

There is clear evidence that both needle syringe programmes and medication assisted therapy are effective. A growing literature also demonstrates how cost-effective they are and how great the cost of inaction or ineffective action is. The evidence shows the returns on investment in effective harm reduction are amongst the highest in public health. This evidence has led several countries to implement proven, effective harm reduction approaches but much more needs to be done. A growing number of studies have examined the efficiency and cost effectiveness of different harm reduction delivery models and these studies enable us to increase the scope, coverage and economy of harm reduction. The lessons of these studies are examined. Harm reduction is amongst some of the most rigorously evaluated and best proven public health interventions. This evidence needs to be communicated more effectively to policy makers, while we continue to address other non-scientific obstacles to rational harm reduction approaches. We also have sufficient experience and evidence to further improve the scope, coverage and efficiency for harm reduction.

957 Tobacco harm reduction: will we see a public health triumph or a defeat for harm reduction? P3

Replacing smoking with a smokeless delivery system for the primary drug, nicotine, can reduce risks by about 99%, which is basically as good as abstinence. Because smoking is so popular, the total potential health benefits from tobacco harm reduction (THR) dwarf those from any other area of harm reduction.

Substitution of oral smokeless tobacco is the only proven method of reducing smoking rates below about 20% in any population where smoking has become popular. With the creation of an increasing array of appealing smokeless tobacco products and electronic vaporizers ("e-cigarettes"), the potential appeal of substitution is increasing. THR is potentially a lynchpin from a socio-political standpoint, possibly foreshadowing the future of other harm reduction efforts. The enormous resources devoted to tobacco-related activism mean that whatever happens will have spillover effects. The harm reduction philosophy has helped establish humane, realistic policies for other behaviours that recognise users as having legitimate preferences and a central role in regulations that affect them. However, most anti-tobacco activism is focused on abstinence-only, elimination of legal markets at all costs, and demonising users, treating them as mere objects to be manipulated. As a result, there is active and effective opposition to THR which has caused severe harm to public health (by preventing implementation of an effective anti-smoking approach) and removed concern for users' welfare from the policy discussion. Due to the scope and visibility of tobacco use, if THR is widely adopted, it will make it difficult for harm reduction opponents to deny its legitimacy. However, if anti-tobacco extremists succeed in preventing THR, further marginalising and even criminalising tobacco use, it might be a gateway for them and others to direct their resources to supporting heavy-handed vilification and abstinence-based policies toward other behaviours.

1167 The United States President's Emergency Program for AIDS Relief (PEPFAR): progress and challenges in building country-level capacity for comprehensive HIV prevention for persons who inject drugs P3

This presentation will report on recent developments in US policy related to planning, implementing, monitoring and evaluating comprehensive HIV prevention programmes for people who inject drugs in the U.S. President's Emergency Plan for AIDS Relief (PEPFAR).

As part of the 2010 financial appropriations process, the US Congress lifted the ban on domestic funding for needle and syringe exchange programmes. On July 10 2010, the PEPFAR released a revised technical guidance document on Comprehensive HIV Prevention for People Who Inject Drugs. This guidance affirmed PEPFAR's support for comprehensive, evidence-based, and human rights-based HIV prevention programmes for persons who inject drugs. As part of this guidance, PEPFAR explicitly allowed funding to be used for needle and syringe exchange programs as one component of comprehensive HIV prevention programmes among persons who inject drugs along with medication assisted treatment, ART and other interventions. Changes in the law, the release of the guidance and technical assistance to countries in different regions of the world, including sub-Saharan Africa, has resulted in increased funding for a more comprehensive and evidence-based approach to HIV prevention for persons who inject drugs. Current and future major challenges in introducing and scaling-up prevention and treatment for persons who inject drugs in these countries will be discussed.

1168 Forfeit of stand fast: human rights of people who use drugs P3

My life is a mirror reflecting the fate of millions of people who use drugs in Russia and most of the former Soviet countries. My beliefs have faded away by undeclared promises of the officials; I have nothing to lose as my health has gone, many of my friends have died of AIDS, TB and overdoses; I am tired of begging the authorities to fulfill their legal obligations. Drug users in Russia often suffer ill-treatment and punishment, lack of access to medical help, infringements of the right to privacy and freedom of expression, violation of other human rights and freedoms. I have chosen an open demand for my rights through international human rights bodies. Although it is too early to conclude on whether or not my complaints would bring any positive changes in the position of the Government, there has been already one clear achievement: many people who use drugs in my country received a clear message for the first time in their life: we have rights to defence and the defence is possible. This gives us hope for positive changes in future.

Wednesday 6th April 2011

14:00–15:30

Banquet Hall 1+2

Chair: Damon Barrett

C21

The harms of criminalisation

Daniel Wolfe

633 Outside the law: de facto criminalization, socio-structural risk, and HIV/AIDS

Eka Iakobishvili

165 Judicial corporal punishment for drug related offences

Pavlo Skala

543 Criminal prosecution of medical staff involved in SMT programs impedes counteracting HIV/AIDS epidemic in Ukraine

Mikhail Golichenko

906 Use statistics to get more sticks: punitive aspects of the new drug laws in Ukraine

Banquet Hall 3

Chair: Carl Phillips

C22

Obstacles to reducing tobacco-related harm

Katherine Devlin

251 The World Health Organization cares about tobacco harm reduction (or do they)?

Karyn Heavner

965 Tobacco harm reduction regulations in the US and the European Union: a race to the bottom or a race to the top

Sudhanshu Patwardhan

809 A survey of healthcare professionals in the UK, Sweden and Norway on their attitudes about the role that tobacco harm reduction can play in helping reduce public health impacts of tobacco use

Paul Bergen

810 The trend toward banning flavoured tobacco products: unethical policy that threatens harm reduction

Banquet Hall 4

Chair: Andrej Kastelic

C23

Preventing and treating hepatitis C

Holly Hagan

835 A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs

Magdalena Harris

320 Venous access and track mark avoidance: harnessing pragmatic concerns in HCV prevention interventions

Robert Bruce

838 Developing a modified directly observed therapy Intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication

Don Des Jarlais

376 Intranasal drug use as a component of "combined" prevention of hepatitis C virus transmission among injecting drug users: New York City, 2005–2010

15:30–16:00

16:00–17:30

Banquet Hall 1+2

Chair: Adeeba Kamarulzaman

C26

Researching epidemics

Peter Vickerman

862 Is the HCV co-infection prevalence amongst HIV infected IDUs a proxy marker for the level of sexual and injection related transmission of HIV?

Emma White

1118 A mathematical model for injecting drug-use, HIV-infection and the treatment-relapse cycle

Peter Higgs

708 Reducing the impact of hepatitis C infection: deciphering how and why it spreads

Pedro Mateu-Gelabert

374 "Planning ahead for safety": IDUs who plan ahead may enhance injection safety for themselves and their network

Banquet Hall 3

Chair: Jamie Bridge

C27

Key issues and innovations in harm reduction practice

Liz Evans

1142 Community, belonging and cupcakes: going beyond housing first

Olga Balakireva

776 First injection drug and the conditions of the first injection drug use in Ukraine

Gillian Kolla

377 Helping to give a first hit – exploring the process of initiation to injection from the perspective of the "helpers"

Doaa Oraby

545 Outreach workers supporting behavior change among injecting drug users: an adapted and effective harm reduction approach in Egypt

Banquet Hall 4

Chair: Robert Gray

C28

Compulsory drug detention in Asia

Sara Bradford

705 Arbitrary arrest and the disappearance of drug users in Cambodia

Theodore Hammett

681 Reforming Vietnam's drug "rehabilitation" system

Risa Alexander

717 Turning prison into paradise: humanizing drug treatment in Indonesia

Richard Pearhouse

1107 Drug detention centers in Asia: research and advocacy during 2010–2011

Dato' Zuraidah Haji Mohamed

1080 How advocacy and transformational leadership have helped change Malaysia's treatment of drug dependants

13:00–17:30

DIALOGUE SPACE

12:30–13:00

launch of the 'International Journal on Human Rights and Drug Policy'

13:00–14:00

Decriminalisation in Portugal – João Castel-Branco Goulão – Portuguese Drugs Czar

14:00–15:00

Meet the Leaders: The Global Fund and partners

14:00–14:30

Advocating for harm reduction: the role of civil society advocacy networks

15:00–15:30

INPUD: structural violence, stigma, discrimination and drug user organising

15:30–16:00

Meet the sex work activists

16:00–16:30

DIY detox

16:30–17:30

Naloxone panel

AFTERNOON

CONCURRENT SESSIONS

Rabieh **C24**
Chair: Anke van Dam
Syringe exchange: impacts and challenges
Ryan Kling
685 Controlling HIV epidemics among IDUs in Northern Vietnam and Southern China: 7 Years of cross-border interventions
Taing Phoeuk
786 The association between NSP suspension and rising HIV among IDUs, especially women, in Phnom Penh, Cambodia
William Zule
601 Should needle and syringe programs give IDUs what they want or what they need?
Celine Debaulieu
570 Starting comprehensive harm reduction in Temeke District, Dar-es-Salaam, Tanzania

Hamra **C25**
Chair: Patricia Kramarz
Issues in delivering effective opioid substitution therapy
Sarz Maxwell
961 Buprenorphine for opiate substitution therapy: adequate dosing
Perrine Roux
590 Adherence to opioid substitution treatment among HIV-infected injecting drug users: the importance of paying attention to withdrawal symptoms
James Bell
274 Case studies in injectable opioid treatment
Olivier Vandecasteele
1058 Designing the national methadone maintenance treatment protocol for the Islamic Republic of Afghanistan

WORKSHOPS

11:00–12:30
 What does a multi-sectoral service system for drug users look like?
12:45–14:15
 Opioid Substitution Treatment in practice
14:30–16:00
 Building capacity for youth friendly harm reduction
16:10–17:40
 Estimating the size of most at risk populations

For further details on the workshops sessions please refer to the *Dialogue, Debate and Workshops* handout.

TEA/COFFEE BREAK

CONCURRENT SESSIONS

Rabieh **C29**
Chair: Rebecca Ann Schleifer
Street lawyers and harm reduction
Emil Kiørboe
551 Does street lawyering work?
Hajdi Shterjova Simonovikj
849 Good harm reduction practice: free legal aid for sex workers
Umra Omar
836 Integration of legal support into harm reduction services to advance the health and human rights of drug users in Eastern Africa
Ricky Gunawan
1152 A community legal empowerment for PLHIV and transgender's in Indonesia

Rabieh **C30**
Chair: João Castel-Branco Goulão
Opportunities for harm reduction and drug policy in Africa
 This session is a panel discussion and will not include full presentations. Participants will discuss drug policies, development work and new harm reduction services in Africa.
Daniel Maro, Muhimbili University of Health and Allied Sciences, *Tanzania*
Danny Volcere, SOLIDER, *Seychelles*
Femi Fasinu, Youth Dignity International, *Nigeria*
Taib Abdulrahman Basheeb, Reachout Centre Trust, *Kenya*
Susie Mclean, International HIV/AIDS Alliance, *United Kingdom*

DEMONSTRATION AREA

10:30–11:00
 Overdose response
12:30–13:00
 Female condoms
13:00–13:30
 Tobacco harm reduction
13:30–14:00
 Needles and syringes
15:30–16:00
 Crack cocaine harm reduction

For further details on the demonstration area sessions please refer to the *Dialogue, Debate and Workshops* handout.

12:30–17:55

FILM FESTIVAL

LUNCHTIME 12:30–14:00

12:30 Smokescreen (Brazil)

SYMPOSIUM 14:00–15:30¹

14:00 W Takhatayna el Houdoud – Beyond Limits (Lebanon)
14:27 Cocaine Part three – Leo and Ze (UK)

LOUNGE 15:45–18:00

15:45 Yajilarra (Australia)
16:12 Our Drugs War Part Three: Birth of a Narco-State (UK)
17:00 CUT conference advocacy (Mauritius)
17:12 HIV shoots up (UK)
17:23 Way to Recovery (Tajikistan)
17:44 In His Own Words – The Story of P' Boy (Thailand)
17:50 The Nicotine Myth (UK)
17:55 Under the rug (Canada)

¹ Timings for symposium sessions include running time of film plus 10 mins speaking time

Thursday 7th April 2011

MORNING

09:00–10:30

MAJORS

Banquet Hall 1+2

M13

Chair: Ingrid van Beek

Naloxone

Roxanne Saucier

432 Bringing the power home: starting your own overdose prevention and response program

Nabarun Dasgupta

368 Community activation and empowerment through naloxone and overdose prevention in the rural United States

Elena Borzunova

373 Antidote to apathy: the effects of overdose programming on a harm reduction organization

Tuan Nguyen

663 Saving lives with naloxone – stories of drug users in Vietnam

Banquet Hall 3

M14

Chair: Thierry Charlois

The risk environments of drug use and sex work

Lisa Maher

275 A hard sell – safe sex in unsafe spaces: negotiating the sex work risk environment in Phnom Penh, Cambodia

Martin Choo

647 HIV risk environment from a rapidly modernising Malaysian fishing industry: a call for structural harm reduction intervention.

Samuel Friedman

168 Dignity-denial, the social production of harm, and the dialectics of resilience and resistance

May Myat Thu

518 Women who use drugs: do we care in Myanmar?

Banquet Hall 4

M15

Chair: David Wilson

Economics and effectiveness

Sergey Votyagov

724 The use of harm reduction economic analysis in advocacy in EECA

Igor Oliynyk

555 Investments in harm reduction: sub-analysis of Global Fund-supported interventions in prison settings

Natasha Martin

1009 The utility and cost effectiveness of hepatitis C antiviral therapy for prevention amongst active injecting drug user populations

Robert Gray

736 Russian Naloxone Project provides model for building legal, sustainable, & cost efficient naloxone supply to reduce mortality among drug users

10:30–11:00

TEA/COFFEE BREAK

11:00–12:30

MAJORS

Banquet Hall 1+2

M16

Chair: Ruth Birgin

Families, parenthood and drugs

Daria Ocheret

1053 Motherhood, child custody and drug use in Russia

Kate Iorpenda

566 Neglected families

Zainab Fazil

280 The social and economic impact of drug use on families: a qualitative insight

Keiko Cornale

758 Often forgotten: the children of people who use drugs

Banquet Hall 3

M17

Chair: John-Peter Kools

New trends and patterns of drug use: mephedrone and prescribed opioids

Mukta Sharma

117 Pharmaceutical diversion and misuse in Asia: a review of current patterns and public health consequences

Amanda Roxburgh

310 Oxycodone deaths in Australia – 2001 to 2009

Alena Vladimirovna Asaeva

1055 Russia: new trends in drug use lead to severe health consequences and death among IDUs

Mirjan Svagelj

1147 New drugs, new challenges, new approaches

Banquet Hall 4

M18

Chair: Eka Iakobishvili

Human rights

Joanne Csete

894 People who use drugs, HIV, and human rights

Patrick Gallahue

419 Human rights impact assessments as a safeguard against abusive practices

Tatyana Margolin

864 Using the optional protocol to CEDAW to protect the rights of IDU women

Wen Wang

313 The influence of a former user's legal appeal against indiscriminate urine testing

12:30–13:30

LUNCH BREAK

PLEASE REFER TO PAGE 19 FOR THE PRESENTATION ABSTRACTS

AFTERNOON

13:30-15:00

PLENARY SESSION

P3

Banquet Hall 1+2*Chair:* Mukta Sharma**Promoting change**

#1168 in Russian (headsets!)

David Wilson**1166** Effectiveness and cost-effectiveness of harm reduction**Carl Phillips****957** Tobacco harm reduction: will we see a public health triumph or a defeat for all harm reduction?**Rich Needle****1167** The United States President's Emergency Program for AIDS Relief (PEPFAR): progress and challenges in building country-level capacity for comprehensive HIV prevention for persons who inject drugs**Irina Teplinskaya****1168** Forfeit of stand fast: human rights of people who use drugs

15:00-15:30

TEA/COFFEE BREAK

15:30-16:45

CLOSING SESSION

Closing Session**John-Peter Kools**

Chair of IHRA

Elie Aaraj

Director, SIDC and MENAHRA

Donya Aziz

Member, National Assembly, Pakistan

Awards ceremony:

- National Rolleston Award
- Travis Jenkins Award
- Film Festival Award

Paddy Costall

Conference Consortium

Rick Lines

International Harm Reduction Association

John Ryan

Anex, Australia

POSTER PRESENTATIONS

The posters index shows up to three authors for each submission, with the presenting author highlighted. Full list of authors can be found on the conference CD, in the abstracts book.

"ADVOCACY AND POLICY" POSTER SESSION (MONDAY, 4TH APRIL)

ID	Board Number	Title	Authors
131	1	Healing the dragon: Heroin use disorders and HIV/AIDS – an approach to management within the South African context	Monika dos Santos, John-Peter Kools, Franz Trautmann
139	2	Sexual Health Rights intervention policy and strategy excludes Third Genders (TG) and TG Sex Workers in Nepal	Saroj Nepal
203	3	The rights of women IDUs in Ukraine	Liliya Grynyuk
218	4	Implication of legislation research on HIV/AIDS and drug's problems for development of sustainable Harm Reduction strategy in Azerbaijan	Arzu Mamed Guliyeva
229	5	Eastern European Drug users in the Netherlands	Ineke Baas
232	6	Inadequate pain management in the Russian Federation	Elena Romanyak, Ilya Lapin, Natalia Khodakevich
237	7	Government & harm reduction	Sumit Thapaliya
239	8	The French 1970 laws on drugs are incompatible with our health!!!	Christian Andreo, Arnaud Simon
240	9	Social drivers of drug-related harms among IDUs: Research to assist users groups, harm reduction organizations and public health agencies to plan political and policy long-term agendas	Samuel Friedman, Enrique Pouget, Barbara Tempalski
277	10	Building capacity, the challenge of redressing harm reduction neglect in Latin America	Silvia Inchaurrega
284	11	Redressing neglected harms of punitive laws in Argentina	Silvia Inchaurrega
291	12	Silent epidemic among women drug users	Govind Karki
297	13	Prevention of post-release overdose deaths	Lars Moller, Ms Mackenzie Bisset, Brenda van den Bergh
300	14	Integrating TB into HIV	Regina Bhebhe
305	15	Methadone Maintenance Therapy in Malaysia: Urgent Needs for Low Regulated Model	Rusdi Abd Rashid, Noorzurani Robson, Hussain Habil
308	16	Friend or foe? Mobilising local stakeholders to increase access of people who inject drugs to harm reduction programs	Andrew Sinclair
316	17	The Role of NSEP as Tool for Strengthening MMT program: A SAHABAT Experienced	Nasir Mohamad, Ahmad Zaeri Latahir, Nor Hidayah Abu Bakar
325	18	Critical factors for the involvement and participation of drug users	Katrin Schiffer
348	19	Media portrayal and community perceptions of the Sydney Medically Supervised Injecting Centre, 2001–2010	Ian McPhail Flaherty, Marianne Jauncey
357	20	Preventing human rights violations in relation to drug addicts who are in places of temporary detention and in Poltava Prison	Roman Antonovych Drozd
385	21	A Women's Drug Clinic in Iran: Methadone treatment improves psychosocial outcomes for highly dependent heroin users and maybe preventative for less dependent users	David Allsop, Shabnam Salimi, Bijan Nassirimanesh
392	22	Designing Advocacy Strategies for Obtaining HCV Treatment for Injecting Drug Users in Thailand: A Community-based Organization's Experience	Noah Thomas Metheny
397	23	"Perspective of harm reduction from the ground reality in the context of human rights"	Rajesh Khongbantabam
403	24	The war against stigma and discrimination – Malaysian experience	Mohd Zaman Khan Rahim Khan
407	25	Dynamics of establishing agonist substitution therapy in Georgia	Gela Lezhava, Irakli Gamkrelidze
424	26	Narghile (Hookah, Shisha, "waterpipe") Smoking and Harm Reduction: Redressing Neglect about Its Modern Fashionable Form	Kamal Chaouachi
431	27	Build up your national red cross/red crescent society's harm reduction capacities in following the ukrainian model	Susanna Mnatsakanova, Jurgen Pletsch
464	28	Knowledge of Harm Reduction in law enforcement agency staff	Yun Lin
478	29	Taking the legal route: Development of provincial regulations in harm reduction	Simplexius Asa, Rudhy Wedhasmara, Patri Handoyo

"ADVOCACY AND POLICY" POSTER SESSION (MONDAY, 4TH APRIL)

ID	Board Number	Title	Authors
487	30	The UN: Aiding abuse in Cambodia?	Sara Bradford
502	31	Designer Drugs and Harm Reduction	Mirjan Svagelj, Mina Pas, Barbara Purkart
522	32	EHRN report on best practices for tackling hepatitis C in IDU populations in Europe	Rasa Cicenieni
523	33	Substitution Treatment in Pretrial Detention Units!	Oleksiy Kotvytsky
524	34	Peers' Perspective: Is labeling as "peer" needed in Harm Reduction?	Thinzar Tun, Willy De Maere, Zaw Baw
527	35	The Interconnections between Pain Management and Illicit Drug Policy	Tamas Varga
529	36	Polish Prisons: Improving Access to Substitution Treatment – reality, quality, challenges. An advocacy project	Agata Kwiatkowska, Grażyna Konieczny, Artur Lutarewicz
530	37	Implementation of "in group analysis method" for strengthening networks for harm reduction in IDUs in Morocco	Soumaya Rachidi, Kamal Alami, Pierre Huygens
536	38	II Latin American Conference on Drug Policy: towards a non-punitive approach	Pablo Cymerman, Diana Rossi, Graciela Touze
540	39	Small amounts of drugs for personal use: a bitter lesson to be learnt from Polish drug policy	Mateusz Klinowski, Agnieszka Sieniawska, Grzegorz Wodowski
562	40	Sexuality and substance abuse: a social view	Chinedu Onyedikachukwu Oraka
595	41	Developing Harm reduction in South Africa; Responding to emerging drug use in the centre of the global HIV epidemic	John-Peter Kools, Franz Trautmann
606	42	2 Decades of Peer based Needle Exchange New Zealand	Susan Forbes, Rachel Browne
607	43	Auto-disable syringes and safe medical injection: Impact on injecting drug users	Sharon Stancliff
618	44	Why it matters which Ministry is responsible for health of prisoners	Peter Wiessner, Raminta Stuikyte, Heino Stöver
622	45	The Right to Live without Tuberculosis	Kostiantyn Zverkov
627	46	Addressing health inequities for same sex attracted women in New South Wales, Australia, who use drugs	Angela Matheson, iri May
628	47	Women who use drugs and their children in Russia: pushing for safe motherhood	Evgenia Maron, Irina Maslova
659	48	Collaboration of NGO with Community Health Centre in Central Java: Towards a sustainable comprehensive harm reduction package	Ligik Triyogo, Yunus Pasetyo, Dr Suwari
671	49	A prospective cohort study of ex-prisoners with a history of injecting drug use in Melbourne, Australia: findings and recommendations for policy and practice	Brendan Thomas Quinn, Rebecca Winter, Amy Kirwan
680	50	Healthcare Providers Drive the reuse of Syringes for Therapeutic Injections and the Potential for Generalized Epidemics of HIV and HCV in Pakistan	Adnan Khan, Rashid Jooma, Huma Qureshi
696	51	Opioid Substitution Treatment in Custodial Settings	Andrej Kastelic
700	52	Learning from mistake: Community Mobilization a key to success in harm reduction services	Sok Chamreun Choub, kimhai So, Chansopha Ly
703	53	To Defend Interests of Drug Users and Advocacy of Their Rights	Konstantine Labartkava, Lana Lagvilava
707	54	Community advocacy to tackle ARV treatment shortages in Russia	Anastasia Solovyeva
731	55	Criminalization of opioid users in Ukraine now 100 times higher than in Russia! Potential and real risks	Pavlo Skala, Ludmila Maistat
743	56	New phase of harm reduction in Kyrgyzstan: towards access to hepatitis C treatment	Ulan Dastan Uulu, Aibar Sultangaziev, Raminta Stuikyte
756	57	Rising HIV infection among IDUs in Pakistan in an era of constrained resources: An urgent call for action	Sajid Ahmad, Faran Emmanuel
763	58	Harm reduction field within municipal drug policies: benefits and challenges	Thierry Charlois
779	59	Marijuana Markets in the Czech Republic and in the U.S. – different drug policy approaches and harms	Vendula Belackova, Tomas Zabransky
789	60	Tobacco Control Legislation: The Lebanese Experience	Jade Boulos Khalife, Georges Saade
793	61	The Impact America's Drug Policy on Harm Reduction Services in Developing Countries	Katya Burns
794	62	Harm reduction programs as tool for guaranteeing the Human Rights of vulnerable population in Azerbaijan	Sharafat Rafiq Ismayilova
808	63	Forced withdrawal: The Ethical dilemma of drug treatment courts in Canada	Patricia Allard

"ADVOCACY AND POLICY" POSTER SESSION (MONDAY, 4TH APRIL)

ID	Board Number	Title	Authors
815	64	Mobilizing PLWHUD and PLHIV through SIMONA+ project: gathering facts for advocacy of access to treatment of HIV, TB/HIV and drug addiction in Russia	Evgenia Maron, Anastasia Meylakh, Albert Zaripov
816	65	Failed drug-supply policies in Mexico. Their impacts on forests	Eduardo Arenas
824	66	Active drug users housing	Serge Longere
834	67	Cruel, inhuman and degrading treatment against sex workers drug users in detention in South Kivu, DRC: What plea for protection against transmission of HIV?	Mihigo Ombeni Alphonse
843	68	Perception Health Access for Drug users. Lesson learned a collaborative work between JANGKAR and Police in Indonesia	Netty Sandra Devi, Sahrul Syah, Bahrul Ulum
885	69	Rehabilitation is Key component of Harm Reduction	Bishnu Sharma, Jeevan Ghale
889	70	Discrimination and Activism in Argentina: How many drug-user activists in Argentina need to die due to discrimination for the State to notice?	Martha Inés Miravete Cicero, Stella Ortega, Erika Smith
890	71	Advocacy for equality perception to support the Needle Syringe Program in East Lombok Region, Indonesia	Frederik Malada
891	72	Reducing the Spread of HIV and Viral Hepatitis: A Generation of Lessons Learned from Syringe Exchange in New York City	Richard Curtis, Robert Cordero
898	73	To Analyze Harm reduction Activities in Prisons of Islamic Republic of Iran	Bahman Ebrahimi, Marziyeh Farnia, Mohamad Shahbazi
915	74	Ill-treatment as state policy: can Russia face the scrutiny of the Committee against torture?	Mikhail Golichenko, Irina Teplinskaya
922	75	Building a global campaign for access to Hepatitis C treatment	Azadeh Momenghalibaf, Raminta Stuikyte, Els Torreele
923	76	Service Interruptions: Harm Reduction and Prisoners	Seth Clarke, Mooky Cherian
932	77	Advocate for drug users rights: self-support groups in Morocco	Fatima Asouab, Foizia Bouzzitoun, Mohammed Bentaouit
938	78	Moving Beyond Drug Courts: Towards a New, Cost-Saving Paradigm to Address the Medical and Public Health Problem of Drug Misuse	Theshia Naidoo
941	79	Pregnant Women: Another Casualty of the Drug War	Theshia Naidoo
944	80	Organizing in Hard Times: Successful Advocacy Campaigns for New Drug Policies in the U.S. and Beyond	Gabriel Sayegh, Jasmine Tyler
953	81	Proposition 19: Changing the conversation about marijuana prohibition in the United States	Laura Thomas, Theshia Naidoo
963	82	Bringing supervised injection facilities to the United States, one city at a time	Laura Thomas
967	83	Scaling up OST within prisons for continuity of care in the Republic of Moldova	Vitalie Slobozian, Silviu Gheorghe Ciobanu, Ilona Burduja
977	84	The Vienna Declaration: A case study on generating public support for policy reform	Michaela Montaner, Christine Tapp, Dan Werb
982	85	First results of hepatitis C advocacy in Georgia	David Otiashvili, Ketevan Bidzinashvili, Zurab Danelia
986	86	It's not just behavior-change! The Indonesian Experience	Ingrid Irawati Atmosukarto
1007	87	Challenges to treating heroin addiction in Malaysia	Noorzurani Robson, Rusdi Rashid, Hussain Habil
1008	88	Stigma, human rights, and the right for treatment	Robert Haemmig
1030	89	KHAT chewing situation in UK	Mohamud Mohamed Fidar
1033	90	Rights to existence & inclusivity – addressing the balance & redressing neglect	Gill Bradbury, Parina Subba
1034	91	Using National data estimates of injecting heroin use amongst young Indonesia to advocate for policy and services	Yudha Wahid, Samuel Nugraha
1035	92	Prevalence of sexual practices among IDUs and need of Targeted Intervention	Suresh Kumar Badhan, Sonal Badhan, Neeti Goswami
1040	93	Integration of services for IDUs in state social and medical systems	Nataliya Gayvoronskaya

"ADVOCACY AND POLICY" POSTER SESSION (MONDAY, 4TH APRIL)

ID	Board Number	Title	Authors
1042	94	Street Harassment: An under researched form of Gender based violence	Suresh Kumar Badhan, Neeti Goswami, DK Taneja
1063	95	Advocating Drug Policy Reform in Hungary	Peter Sarosi
1064	96	Socio-economic barriers for IDU accessing HCV treatment in Indonesia	Yudha Wahid, Samuel Nugraha
1066	97	Criminal prohibition of drug possessing – changes of drug policy in Poland	Barbara Grabowska
1079	98	Stop TB policy in Iranian prisons	Mohammad Shahbazi, Marziyeh Farnia, Ramin Alasvand
1082	99	The Impact of Police Violence on Harm Reduction Services for Sex Workers: Two Case Studies in the CEE/CA	Anna-Louise Crago, Aliya Rakhmetova, Nataliya Isaeva
1095	100	15 years of Harm Reduction in Lithuania: successes and challenges	Aleksandras Slatvickis
1104	101	Law Enforcement Assisted Diversion: Reducing the Harm of Drug Law Enforcement	Kris Nyrop
1105	102	Levamisole Contamination in Cocaine	Kris Nyrop
1114	103	Human Rights and Harm Reduction, Challenges and outcomes of Rosario Programme	Silvia Inchaurrega, Andrea Celentano, Oscar Montenegro
1138	104	Ithemba Counseling Centre – innovative harm reduction practice	Annaliese Rachel Rix
1141	105	Community reactions to needle syringe exchange programme (NSEP) to reduce HIV infections among drug users not in treatment in Malaysia	Baba Ismail
1144	106	The implications of drug policy and law reform for international development and security	Martin Powell
1145	107	How legally regulating drug markets could help protect child health and wellbeing	Martin Powell

"PRACTICE" POSTER SESSION (TUESDAY, 5TH APRIL)

ID	Board Number	Title	Authors
121	1	Collaborative ART Centre of Excellence	Himal Chandra Gurung
123	2	Community-based rapid HIV testing for drug users in low-threshold services	Dirk Schäffer
149	3	harm reduction programmes in Democratic Republic of Congo	Jacques Lundja, Asha Jeanne
174	4	ERLI project: an individual-based educational program for injecting drug users in France	Debrus Marie, Avril Elisabeth, Rogissart Valère
181	5	HIV/AIDS and drug abuse prevention in Central Asia	Ernest Robello
212	6	Scaling up coverage and quality of HIV & AIDS Prevention targeted to most at risk population; Treatment, care and support services for PLHA	Binod Gurung
273	7	Re-implementation of Methadone in Nepal	Sanjeev Rai, Smita Shrestha, Dipak Rai
289	8	11 years of Harm reduction in prisons of Moldova – Successes and challenges	Veaceslav Toncoglaz
290	9	Gaps between HIV knowledge, risk perception and safe sex practice among FSW in the Major Highway of Nepal	Ekta Thapa Mahat
302	10	The importance of implementing harm reduction centers in testing and counseling (C.T.C.)	Felipe David Gomez Bitencourt, Silvio Carlos Tubino Custodio, Vainer Darci Ribeiro Rosa
327	11	Improving the effectiveness of a hepatitis C campaign aimed at drug users	Ineke Baas, Agnes Van der Poel, Lars Van Driel
338	12	Mindful smoking: An Innovation in Drug Treatment	John Williams
344	13	Integration of Anti retro Viral Therapy and Oral Substitution Therapy in Nepal	Tul Prasad Pun
352	14	Think outside the disease box	Aung Yu Naing, Kyaw Thu Hein, Than Min Htike
353	15	Social Methadone: Model Methadone Maintenance (MMT) Program in Nepal	Ravi Krishna Shrestha, Anan Pun, Ujjwal Karmacharya
359	16	Helsinki Deaconess Institute walk-in clinic for HIV positive IDUs	Anna-Maija Strömberg, Sanna Häkklä
365	17	Building bridges with the community of un-reached Chinese Immigrant Injectors' in Aubervilliers, a town in the suburbs of Paris, France	Steven Bucknall, Sandie Sempe
387	18	Safer Sister Initiative: Come back safe!	Alija Kharel, Anjani Karki
394	19	A substitution program staff perspective on drug use services: Embracing reaching out beyond all limitations & ejecting conventional practices	Sunil Aheibam
404	20	Methadone Maintenance in the Raw: Cambodia	Taing Phoeuk
425	21	Capacity building for professional peer-led harm reduction in Thailand	Alex Duke, Verapun Ngamtee, Lawan Sarovat
433	22	Mobilizing IDU Peers to Advocate for Peer-based Harm Reduction in Thailand	Alex Duke, Verapun Ngamtee, Lawan Sarovat
434	23	Improving Thailand's National Harm Reduction Model Using Private Sector Marketing Planning	Alex Duke, Verapun Ngamtee, Lawan Sarovat
457	24	Making the difference: Community Based Harm reduction Initiative in Nepal	Anan Pun, Ujjwal Karmacharya, Subash Rai
459	25	IDU Community involvement for enhancing the quality of harm reduction services in Northeast India	Sentimoa Tzudir
461	26	How effective a local rehabilitation organization to address Drug issue in Quetta, Pakistan	Hameed UI Mehdi, Nasir Mehdi, Asfaq Hussain
470	27	Using computer software to make methadone more accessible and sustainable in Indonesia	James Blogg, Amalah Rahmah, Riza Sarazvita
479	28	Perception of oral substitution program in Nepal... now and then...	Miraz Roshan Thakuri, Ujjwal Karmacharya, Sammpurna Maskey
483	29	Evaluating Tuberculosis Control Program in prisons of Punjab Pakistan	Muhammad Naeem, Darakshan Badar
495	30	Building allies with society figures in campaigning rehab sentence for drug user (du) as a part of implementing harm reduction in west Java, Indonesia	Lili Herawati
499	31	Advocate for Injecting Drug Users legal and Health Services	Taib Abdulrahman Ahmed Basheeib

"PRACTICE" POSTER SESSION (TUESDAY, 5TH APRIL)

ID	Board Number	Title	Authors
506	32	Prevention of HIV/AIDS Among Injecting Drug Users as a Vulnerable Population	Faizah Hamid Mahfudh, Taib Abdulrahman Ahmed Basheeb
508	33	Methadone maintenance therapy programme in Casablanca Morocco	Zineb Haimeur, Soundous Seddiki, Soumia Berrada
512	34	India's National Aids Control Organisation (NACO) implementing harm reduction through civil society	Neeraj Dhingra, Aditya Singh, Aradhana Johri
517	35	TB: a gateway to prison access	Aung Yu Naing, Soe Thet Lwin, Sein Mya
518	36	Women who use drugs: do we care in Myanmar?	Aung Yu Naing, Thit Thit Aye, May Myat Thu
526	37	The efficiency of the model «Peer Driven Intervention» among the women of commercial sex and positive experience of realization of the project on the HIV prevention by the model of «PDI» in Crimea	Aleksander Ganul
537	38	Football Building a Supportive Environment for Harm Reduction and HIV Prevention	Aditia Taslim Lim
539	39	Raising awareness of law on Drugs for Drugs User in Jakarta, Bogor, Depok and Bekasi	Herru Pribadi
541	40	Drop In Center "Escale", Lebanon	Pascale Antoine Al Tannoury, Micheline Samir Abouchrouh, Rita Michel Wahab
544	41	Pharmacy interventions in Ukraine: improving access to services for population groups vulnerable to HIV infection	Galyna Naduta
552	42	HIV Prevention among Female Prisoners in Ukraine	Iryna Mospan
554	43	HIV/AIDS Outreach 2008–2009-SIDC, Lebanon, Funded by Drosos	Nadia Badran
571	44	Women' voices in Harm Reduction Program, Dar-es-Salaam, Tanzania	Celine Debaulieu, Niklas Luhmann
586	45	Drop-in, drop-out (Comprehensive package of harm reduction intervention in Bosnia and Herzegovina)	Samir Ibisevic
592	46	Program Aimed at Training of Peer Consultants from among Prisoners (Ukraine)	Irina Zhelvakova
617	47	C&C 1 Malaysia Clinic: The first step towards decriminalization of drug addicts in Malaysia	Mahmood Nazar Mohamed
630	48	The Big Wheel keeps on Turning... Cutting through the Crap of Syringe Filters	Sarah Elizabeth Hiley, Marguerite White
645	49	Burnout experience and its prevention of an ex-addict working in IDU HIV prevention	Supot Tangsereesup
650	50	Risky Drinking; Blues and Booze	Molly O'Reilly
665	51	Where do methadone clients get their needle syringes from when there is no NSP?	James Blogg, Patri Handoyo, Arif Mulyawan
668	52	Public Universities and Drugs. Involving Harm Reduction in Argentinean Universities	Silvia Inchaurrega, Alicia Donghi, Andrea Celentano
669	53	The Face of Harm Reduction – Community Engagement	Andrea Lee Waite
683	54	Taking a comprehensive approach in impact mitigation for women who inject drugs in Manipur	Sunita Grote, Shasikumar Singh, S. Ranju Singh
688	55	Harm reduction advocacy strategy that challenges policy, practices and structure – Nepal experience	Mahesh Raj Sharma, Bijay Limbu
691	56	Peer-based advocacy to build community support for harm reduction services	Sakda Phueakchay, Wanipa Chantarapanya, Verapun Ngammee
697	57	Indonesian Narcotic Regulation: Subsections Application for Drug User	Rudhy Wedhasmara
701	58	Combining behavior change intervention strategy among NGOs, Community IDUs, and Health Public Services in Dupak, North Surabaya, East Java	Sudiro Husodo, Supriyono Chandra Bhakti, James Blogg
709	59	Community Couples Collaboration for Partners of Injecting Drug Users in East Java Indonesia	Sudiro Husodo, Temma Nifianto, James Blogg
713	60	Lawyer and therapist alliance – The right answer when law cracking down on people	Grzegorz Wodowski, Malgorzata Pawlowska, Agnieszka Sieniawska
720	61	Scaling up methadone maintenance program in Vietnam to reduce HIV and harms associated with drug use: capacity building is key to ensure quality for scaling up	Long Thanh Nguyen, Nhu To Nguyen, Manh Duc Pham
726	62	Stimulant use, psychiatric comorbidity and treatment	Nusa Segrec, Andrej Kastelic

"PRACTICE" POSTER SESSION (TUESDAY, 5TH APRIL)

ID	Board Number	Title	Authors
727	63	Building Community Rehabilitation for IDUs in Yunnan and Guangxi	Jessica Angelson, Rakdaow Pritchard, Hongyun Fu
734	64	Special institution Forchhammersvej, Copenhagen- Harm reduktion in practice	Lotte Monefeldt, Else Nina Carstens
736	65	Russian Naloxone Project Provides Model for Building Legal, Sustainable, & Cost Efficient Naloxone Supply to Reduce Mortality among Drug Users	Robert Gray
753	66	Evaluation of HIV specific legal services together with beneficiaries	Asela Ranjith Lal Kalugampitiya
759	67	Bigger muscles and leaner body by all means? An internet based doping service in Finland	Jukka Petteri Koskelo
760	68	comprehensive interventions to empower IDU partner	Moch Nuroini, Yuli Indrias Mukti
792	69	A Training Programme for Service Providers Working with Women Drug Users and the Spouses of Male Drug Users in South Asia	Katya Burns
796	70	HIV/HCV prevention using buprenorphine at needle exchange programs	Jason Farrell
811	71	Impacting national drug policy: the significance of an NGO project in the field of Harm reduction	Julien Collette, Patrick Gassmann, Miroslav Miskovic
813	72	Reproductive health services integration into the system of narcological help	Maksym Demchenko
817	73	Get closer, get stronger: a long term community-based organization strategy to bring harm reduction to prisoners and to bring the authorities to harm reduction	Sandra Essid, Christian Andreo, Isabel Lefevre
822	74	Harm reduction for young people living in densely populated slums in Nigeria: lessons from "Ajegunle" slum	Femi Aina Fasinu, Sewanu Anna Dejo
832	75	Gender-sensitive approach to HIV prevention among female injecting drug users (FIDUs) in Ukraine: changing philosophy of service provision	Liudmyla Shulga
833	76	Diversification of harm reduction programme in Tajikistan	Zumrat Yakubjanovna Maksudova
842	77	Families affected by drugs, alcohol and crime: how a multi-agency approach is bringing change	Carolyn McDonald
846	78	Integrating HIV/HCV, Mental Health, and Addiction treatments: Models of One Stop Shopping	Robert Douglas Bruce
850	79	Addressing HIV&AIDS among IDUs in the Coast Region of Kenya	Peter Kamau
851	80	Practicing Harm Reduction in Primary Care Settings: The Lesson of Opioids	Robert Bruce, Sarah Bowman
852	81	Motivational interviewing and Harm Reduction Services	Andriy Oleksandrovich Khrapal
858	82	Helping hospitalized smokers	Lourdes Rofes i Ponce, Pilar Roig Cutillas, Antoni Llorc Suárez
859	83	Back from the Brink-Naloxone narratives from Homeless/Hostel Dwellers London	Margaret O'Sullivan
869	84	Relationship between KHAT and Tobacco	Mohamud Mohamed Fidar
870	85	Contribute to the reduction of drug-related health and social harms among individuals, families and communities in Afghanistan	Faramarz Jahanbeen
886	86	The Participant Will See You Now, Doctor	Robert Cordero, Julie Pena, Matthew McClain
887	87	Multi-sectoral and comprehensive prevention and care intervention in HIV to address the detainees of prisons of Moldova	Ilona Burduja, Svetlana Doltu
888	88	Addressing the Gap in Peer-Delivered Harm Reduction to Homeless Women of Color in New York City	Julie Pena, Tamara Oyola-Santiago
892	89	Treating Marijuana Based Concurrent Disorders – A Canadian Cultural Perspective	Geoff Purdy
908	90	VCT with HIV Rapid Tests as a key component of comprehensive services package of harm reduction projects	Viktor Nykolaevych Isakov
925	91	Developing Harm Reduction Programs in Zanzibar	Sharon Stancliff, Frida RadeGunda Godfrey, Redempta Mbatia
926	92	Building a National training and resource centre for Harm Reduction and HIV/AIDS – A key element for cost effective capacity building in resource poor settings	Chloé Forette, Amin Zemaray, Olivier Vandecasteele
935	93	Development of Methadone Centers' Network in Southeastern Serbia during transition period, under the Ministry of Health patronage and Global Fund support 2008–2011	Jelena Milan Matejic, Vladan Radivojevic, Verica Arsenijevic
956	94	Naloxone distribution for peer overdose reversal: Program Development	Sarz Maxwell
958	95	Harm reduction – based treatment of benzodiazepine misuse	Sarz Maxwell

"PRACTICE" POSTER SESSION (TUESDAY, 5TH APRIL)

ID	Board Number	Title	Authors
962	96	From the Ground Up: Building a harm reduction program in Puerto Rico	Tamara Oyola-Santiago, Julie Peña
966	97	Outcome of HCV therapy in HIV/HCV co-infection in real-life clinic (community based and correctional institutional settings) in British Columbia	John Dwight Farley, Wendy Shum, Andy Truong
971	98	Alliance Ukraine implements cost effective SMT models and ensures SMT sustainability	Oleksandr Lebeга, Pavlo Skala
984	99	HIV/hepatitis Testing and Vaccination of Hard to Reach Groups	Astrid Leicht, Manuela Müller-Faerber, Susanne Thate
999	100	Empowerment of female sex workers as a mean of harm reduction – an Egyptian's NGO experience	Abd El Razek Mohamed Abu El Ella, Reda Mohamed Shukry
1004	101	Importance of social support unit in Methadone clinic	Nabin Tulachan , Pradep Malla
1006	102	Drugs in probation	Tre Borràs Cabacés, Antoni Llorc Suárez , Artur Sardà Garcia
1015	103	Harm Reduction Clinic Software/ Proposal for workshop	Mohammad Reza Maziar Faiaznoori , Mohammad Salehi
1020	104	HIV/AIDS and access to ART – Current situation in the Islamic Republic of Afghanistan	Zubair Harooni , Mohammad Aref Shahram, Olivier Vandecasteele
1025	105	Lives of injecting drug users improved through integrated harm reduction services in Kachin, Myanmar	Sujun Zhou
1029	106	Synergistic effect of Treatment Rehabilitation to Harm Reduction Programme – an experience from Nepal	Mahesh Sharma , Bishnu Sharma, Pooja Niroula
1032	107	khat chewing situation for somali communities living in UK	Mohamud Mohamed Fidar
1036	108	The development and use of a dramatically improved, pocket field data collection instrument for IDU peer outreach workers in a provincial city in northern Vietnam	David Jacka, Ngueyn Thien Nga , Nguyen Van Hai
1047	109	Harm reduction Programs in Prison	Marziyeh Farnia, Ramin Alasvand , Mohamad Shahbazi
1048	110	Harm reduction Programs in Prison	Marziyeh Farnia, Bahman Ebrahimi , Ramin Alasvand
1049	111	Harm reduction Programs in Prison/present in workshop	Marziyeh Farnia, Mohamad Shahbazi , Bahman Ebrahimi
1051	112	Effectiveness of Matrix model in treating MMT clients using stimulants	Rahimeh Azimi
1059	113	New Methods of Peer Education	Mohammad Shahbazi , Mohamadreza Keramati, Marziyeh Farnia
1081	114	Working together (Participation of drug users organization in the management of the drug issue at local level)	Antoni Llorc Suárez , Tre Borràs i Cabacés, Maria Paraire Andres
1085	115	"FREE Air" Outreach and research intervention with young People in relation to the use and abuse of drugs in the city of Reus	Antoni Llorc Suárez , Tre Borràs Cabacés, Tamara Gil Castelao
1090	116	Counseling, testing, referral and no treatment for drug users in Ukraine	Pavlo Smyrnov , Tetiana Saliuk, Viktor Nykolaevych Isakov
1097	117	Creating and implementing an HIV outreach prevention program for heroin users in Dar es Salaam, Tanzania: initial lessons learned and ways forward	Daniel Maro , Jessie Mbwambo, Gad Kilonzo
1100	118	Support of the national strategy on harm reduction among drug users in local level: case of the city of Nador, Morocco	Abdelmalek Aouraghe , Abdelouahid Kandil, Soumaya Rachidi
1109	119	Harm Reduction Programme For Drug Users in Poland	Agnieszka Stefaniak
1132	120	Role of NGOs in Harm Reduction Interventions: AJEM experience at Roumieh prison, Lebanon	Hady Aya
1136	121	Ithemba Counseling Centre – HR programme	Annaliese Rachel Rix

"RESEARCH" POSTER SESSION (WEDNESDAY, 6TH APRIL)

ID	Board Number	Title	Authors
134	1	Knowledge, Attitude and Practices Related to Risk of HIV Infection Amongst People Who Are Injecting Drugs (PWID): Case Series Amongst People Who Are Injecting Drugs in Metro Manila	Clemente Abella, Isabel Melgar
167	2	Predictors of transition to injection among rural Appalachian prescription opioid users	Jennifer Havens, Carrie Oser, Richard Crosby
169	3	Art therapy application on addict Female sex workers on maintenance treatment in Iran	Azadeh Bahramji
180	4	Differences in Post-Test Counseling Experiences among Persons Diagnosed with HIV in Jail or Prison versus Elsewhere	Robin Pollini, Estela Blanco, Carol Crump
192	5	Female drug use in Pakistan	Nabeela Nisar
201	6	Predictors of Educational Outcomes of Undergraduate Nursing Students in Alcohol and Drug Education	Hussein Rassool
208	7	Implicit and explicit factors influencing positive prevention among Iranian PLWHAs, a qualitative research	Seyed Ramin Radfar, Abbas Sedaghat, Fardad Dorudi
211	8	Are women who use drugs interested in their personal health? Hormones, hypogonadism and hepatitis C related health among people who inject drugs	Cathy Banwell, Phyll Dance, Anna Olsen
215	9	Efficacy of the Programme KISS (Self-Control of Drug Consumption) in Severely Dependent Drug Addicts: A Randomized Controlled Trial	Gabi Becker, Joachim Körkel, Hans Happel
223	10	"Hepatitis – it's a dirty sounding word ..." Alcohol in the lives of people living with hepatitis C	Michelle Ham, Rachel Sacks-Davis, Peter Higgs
225	11	Social network influences on hepatitis C seroconversion risk	Jamee Newland, Magdalena Harris, Rachel Deacon
228	12	Experience and effective methadone program in Haiphong, Vietnam	Congvan Vu
247	13	Limited access to HIV risk reduction services in South African substance abuse treatment facilities	Bronwyn Myers
250	14	Results of operation research study for developing evidence based gender oriented harm reduction programs for female drug users in Lviv region of Ukraine	Marta Vasylyev, Maryana Sluzhynska, Olexandra Sluzhynska
260	15	Harm reduction interventions informed by a RAR of drug and alcohol use in the spread of HIV and other sexually transmitted infections in Fiji	Robert Power, Elenoa Seru-Puamau, Lucina Schmich
292	16	Easterners shoot other way than Czechs do: Russian speaking IDUs at the Prague open drug scene	Tomas Zabransky, Barbara Janikova, Viktor Mravcik
296	17	Investigation of barriers to condom use among female sex workers in Tehran 2010	Zahra Malayerikhah-Langaroodi, Afarin Rahimi-Movaghar, Shahnaz Delbarpoor-Ahmadi
306	18	Methadone Maintenance Treatment in Mosque setting: An Innovative Strategy	Rusdi Abd Rashid, Hussain Habil, Noorzurani Robson
307	19	Australian Illicit Drug Markets – What's the score? Trends in drug use and related harms	Amanda Roxburgh
317	20	A Herbal Product, Biolitri, Improves Opiate Dependent Individuals on Methadone Maintenance Therapy	Rusli Ismail, Nasir Mohamad, Nurfadhline Musa
335	21	Drug and sexual risk behaviors among impoverished women in Puerto Rico: an exploratory analysis of women living in public housing	Lisa Rose Norman, Lymari Cintron, Carolina Alvarez
339	22	A Women's Drug Clinic in Iran: Significant improvements in women's lives	Kate Dolan, Shabnam Salimi, Bijan Nassirmanesh
340	23	An Iranian Women's Drug Clinic: Reports from women about their journey into drugs	Shabnam Salimi, Bijan Nassirmanesh, Setareh Mohsenifar
347	24	Women clients of the Sydney Medically Supervised Injecting Centre and the agentic self	Ian McPhail Flaherty, Marianne Jauncey
349	25	Trends in prescription opioid injecting at the Sydney Medically Supervised Injecting Centre	Ian McPhail Flaherty, Marianne Jauncey
354	26	Prevention of mother-to-child transmission of HIV among injecting drug users in Ukraine	Ruslan Malyuta, Igor Semenenko, Claire Thorne
355	27	HIV Prevalence Among Injecting Drug Users in the Middle East and North Africa	Ghina Mumtaz, Nahla Hilmi, Laith Abu-Raddad

"RESEARCH" POSTER SESSION (WEDNESDAY, 6TH APRIL)

ID	Board Number	Title	Authors
356	28	Injecting Drug Users in the Middle East and North Africa: Population size estimates and HIV risk behaviors	Ghina Mumtaz, Nahla Hilmi, Laith Abu-Raddad
367	29	The Influence of Fatherhood on Male Injecting Practices and Consumption of Heroin	Tony Knox, Avril Taylor, John Rodger
372	30	Social harm and HIV risk among street-based heroin users in Peshawar	Muhammad Ayub
382	31	Link Between ATS Use and the Transmission of HIV and Other BBVs in the South East Asia Region	Andrea Fischer, Susan Carruthers, Louisa Degenhardt
396	32	Barrier for drug user to access the existing service	Kimhai So
398	33	Understanding and importance of sexual health among drug-dependent women: an exploratory study	Elizabeth Conroy, Lucy Burns, Bridget Spicer
402	34	Estimation of cost-effectiveness the overdose-prevention program in Chapaevsk, Samara region, Russia	Sergey Tsarev, Lyubov Nechaeva, Evgeny Petunin
406	35	Scaling up Needle and Syringe Access in Thailand Using an Evidence-based, Client-Centered Approach	Alex Duke, Duangta Pawa, Robert Gray
408	36	Health related quality of life, Sexual function and depression in patients infected with HIV in Shiraz, South of Iran	Mahmood Amini Lari, Hosain Faramarzi, Mesbah Shams
414	37	Longer-term follow-up of clients from a community-based opioid substitution therapy program in Manipur, India	Michelle Kermode, Gregory Armstrong, Waribam Surmick Singh
436	38	Impact of drug court policies on access to substitution treatment for opiate dependency in New York State	Holly Catania, Joanne Csete
438	39	A Survey of TB in Prisons of I.R.Iran (2004–2009)	Marziyeh Farnia, Ramin Alasvand
445	40	Predictors of antiretroviral therapy discontinuation among HIV-positive injection drug users in Vancouver, Canada	Dan Werb, Ruth Zhang, Julio Montaner
458	41	"HIV – what's that?" Disaster in the making as Pakistani IDUs routinely share syringes (and HIV) on the streets of Bahawalpur	Zeeshan Ayyaz, Kate Dolan
460	42	Already a late stage HIV epidemic for injecting drug users in Bali?	James Blogg, Sagung Sawitri, Rosy Angela
463	43	Crossing border Myanmar IDUs and Chinese IDUs high risk behavioral in Ruili city, China	Jun Rui Zhong
465	44	IDUS Who Sell Sex in Karachi Are Young, Unmarried and Safe – Yet	Adnan Khan, Rashid Jooma, Ayesha Khan
469	45	Ethical position of opponents of opioid substitution therapy and harm reduction in Russia	Vladimir Mendelevich
484	46	The initiation into injecting drug use and the role of male Injecting Drug Users, a behavioral survey in 7 provinces in Vietnam	Khanh Ngoc Vu, Gary Mundy, Tung Duc Pham
491	47	Does Harm Reduction program have an impact on reducing HIV prevalence among Injective Drug Users? –An evidence from Nepal	Sanjay Rijal, Mahesh Sharma, Komal Badal
531	48	Detoxification as harm reduction in Atlantic Canada?	Margaret Dykeman, Lois Jackson, Jacqueline Gahagan
533	49	Injection drug use and harm reduction in rural Atlantic Canada	Joanne Parker, Lois Jackson, Margaret Dykeman
538	50	Access to medical services for HIV-positive IDUs in Ukraine	Anna Koshikova, Konstantin Lezhentsev, Volodymyr Kurpita
546	51	Oxygen Desaturation after Concurrent Injection of Prescribed Heroin and Oral Methadone: A Randomized Cross-Over Experiment	Rob Van Der Waal, James Bell, Mary Chambers
556	52	Social and physical determinants of needle discarding	Luc de Montigny
557	53	Do the offered harm reduction interventions meet the needs of high-risk drug users? Factors influencing acceptance of treatment programs	Małgorzata Zanki, Gabriele Fischer
560	54	Influence of Methadone Maintenance Therapy on injecting drugs and consequences from injecting	Vlatko Dekov
561	55	Assessing the risk of substance abuse, family and sexual violence among adolescents in Nigeria	Chinedu Onyedikachukwu Oraka
576	56	Title: The use of amphetamine type stimulants among injecting drug users (IDUs) from Bucharest, Romania	Catalina Iliuta Serban, Alina Bocai
577	57	Relationship between Attachment styles, Religious coping styles, Social support perception and Mental Health among HIV+ patients	Mahammad Davood Husseini, Parvin Afsar Kazerooni, Javad Molla Zadeh

"RESEARCH" POSTER SESSION (WEDNESDAY, 6TH APRIL)			
ID	Board Number	Title	Authors
583	58	Changes in HIV risk behaviours among injecting drug users (IDUs) in north-east India following scale-up of a targeted HIV prevention response	Chumben Humtsoe , Gregory Armstrong, Mung Ngaihte
584	59	The "Heidelberger Drogenbogen (HDB)": construction and test quality criteria	Jan Weinhold , Corina Aguilar-Raab
587	60	Contextualising drug use: rituals, drug, set and setting	Jan Weinhold
588	61	Challenges in the Injection Room	Sindi Teena Addorisio , Kurt Lock, Martin Schechter
596	62	Impact of inpatient research participation on subsequent drug use patterns	Perrine Roux , Richard Foltin, Phillip Saccone
605	63	An Innovative Research Strategy for Collecting Life History Data Using Both Qualitative and Quantitative Models	Miriam Boeri , Benjamin Tyndall
612	64	Gender vulnerability among women's drug users in the north of Morocco	Fatima Asouab , Mohammed Essalhi, Haj Hnnaba
613	65	Suburban Enclaves of Poverty: Lack of Services for Female Drug Users in US Suburbs Increases Risks of Infections Diseases, Violence, and Rape	Miriam Boeri , Benjamin Tyndall, Denise Woodall
619	66	The Un-MET Study: Exploring the pathways and barriers to utilisation of drug treatment for a prospective cohort of methamphetamine users	Brendan Quinn , Paul Dietze, Cerissa Papanastasiou
625	67	Secondary syringe exchange: a pre-existing, effective and illegal model of sterile injection equipment distribution in New South Wales, Australia	Jamee Newland
626	68	Changing patterns of benzodiazepine use among regular injecting drug users in Melbourne, Australia: Emergence of alprazolam	Danielle Horyniak , Siobhan Reddel, Paul Dietze
629	69	Motivation to injection among methamphetamine smokers in Chiang Mai city, northern Thailand	Tasanai Vongchak , Wittaya Promjuk, Umpava Timpan
639	70	"They don't know how to treat us": The health needs of older opiate using Australians	Peter Higgs , Jennifer Kelsall, Chris Rocks
653	71	Introducing opioid substitution therapy in Kyrgyz prisons	Saliia Karymbaeva , Lars Moller, Emilis Subata
666	72	High syringe coverage among Needle Syringe Program (NSP) attendees in Australia	Jenny Iversen , Handan Wand, Libby Topp
667	73	Is Drop in Center (DIC) effective for Needle Syringe Programme(NSP) – A case study from Nepal	Komal Badal , Sanjay Rijal
675	74	The Neglected Reproductive Health Needs of Sex Workers Who Use Drugs: High Lifetime Pregnancy and Low Contraceptive Usage	Putu Katherine Duff , Jean Shoveller, Jill Chettiar
677	75	HIV prevention for female sexual partners of IDUs in Hanoi, Vietnam: progress and challenges	Theodore Hammett , Ryan Kling, Oanh Thi Hai Khuat
678	76	Overcoming Barriers to ART for IDUs with Peer/NGO Support: Lessons from Pakistan	Ayesha Khan , Abbas Haider, Rizwan Qazi
704	77	Female Injecting Drug Users: the new perspective on HIV Prevention	Liudmyla Shulga , Tatiana Andreeva, Vikotira Artemenko
712	78	Summary of the major findings from an evaluation of the pilot methadone maintenance therapy program in Vietnam	Long Thanh Nguyen , Manh Duc Pham, Tam Thi Minh Nguyen
715	79	Respondent driven sampling vs. community outreach – recruitment of people who inject drugs to a longitudinal study in Sydney, Australia	Bethany White , Anna Bates, Jarliene Enriquez
737	80	A national multi-site qualitative study to identify the specific needs of women who use drugs in France	Lisa Rivasseau , Stephane Giganon, Cynthia Benkhoucha
755	81	The integration of substance use, mental health and homelessness services in Australia	Elizabeth Conroy , Paul Flatau, Lucy Burns
762	82	Rise of mephedrone – a designer drug	Mirjan Svagelj , Mina Paš, Barbara Purkart

"RESEARCH" POSTER SESSION (WEDNESDAY, 6TH APRIL)

ID	Board Number	Title	Authors
778	83	Review of eligibility criteria for methadone maintenance treatment in national protocols of different countries	Alireza Noroozi , Azarakhsh Mokri, Emran Mohammad Razzaghie
782	84	Sexual Behavior of Ukrainian Youth and Personal Risk of HIV Infection	Tetiana Bondar , Olga Balakireva, Olena Sakovych
784	85	Educational Supervision of the injection of drugs: study design and expected outcomes	Le Gall Jean-Marie, Carrieri Patrizia, Arnaud Simon
785	86	Mishwar Study	Mostafa Mahmoud El Nakib , Rima Afifi, Farah Barbir
791	87	Estimation size of most at risk adolescents (MARA) in Ukraine	Olga Balakireva , Olena Sakovych
812	88	Situational Analysis Amongst Commerical Sex Workers in Seychelles 2010	Joseph Rath, Danny Volcere , Benjamin Vel
826	89	A harm reduction approach to education about drugs	Claire Meehan
829	90	Preliminary Assessment of Overdose Cases in Ukraine	Liudmyla Shulga , Anna Tokar
856	91	Declining Prevalence of HIV Infection Among Intravenous Drug Users Testing for HIV at a Federally Qualified Inner-City Community Health Center in New Haven Connecticut, USA	Robert Bruce , Gerald Kayingo, Nesrine Rizk
860	92	Children and drug treatment in the Republic of Maceodnia	Natasha Boshkova , Hajdi Shterjova Simonovikj
863	93	Challenges for drug-using mothers with children in the care of family members	Sydney Weaver
880	94	Harm Reduction: Good but not good enough when measuring the health and wellbeing of opiate users and their children	Catherine Maria Comiskey , Jennifer Milnes
896	95	Occupational and disease risks among women engaged in sex work in Phnom Penh, Cambodia: the vulnerability of freelance sex workers	Marie-Claude Couture , Kimberly Page, Neth San Sothy
897	96	Living But Not Well – Assessing the health and social status of injection drug users in Chengdu, China	Craig Robinson , Duan Kun, Niklas Luhmann
906	97	Use statistics to get more sticks: punitive aspects of the new drug laws in Ukraine	Mikhail Golichenko , Pavel Skala
910	98	Cocaine and problems in socailly integrated users	Mirjan Svagelj , Mina Pas, Barbara Purkart
912	99	Injectors Living in the Suburbs of New York City: Preliminary Findings about an Understudied Population	Lauretta Grau , Lisa Nichols, Wilson Palacios
918	100	The Use of Substitute Drugs to Counteract Problematic Substance Use	David Gibson , Miriam Boeri
937	101	SCS in my backyard? Opinions of community members	Gillian Kolla , Tara Marie Watson, Susan Shepherd
940	102	Mandatory Drug Rehabilitation Centers in Malaysia: Health Status of HIV-Infected Detainees and Implications for Developing Evidence-Based Models of Treatment and Prevention	Jeannia Fu , Alexander Bazazi, Mahmood Nazar Mohamed
948	103	Higher drug-related arrest rates are related to more sexual partners among injectors	Hannah Cooper , Don Des Jarlais, Barbara Tempalski
955	104	Trends in UNGASS Reporting: Demonstrating Commitment to Service Provision & Reporting for IDUs	Clancy Michelle Broxton , Melissa Adams
968	105	Medically Supervised Injection Centre Activity and Its Function In a Drug Out Clinic Centre	Nieves Martínez-Luna, Begoña Gonzalvo , Carlos Roncero
969	106	Harm Reduction Programs and Psychiatric and Substance Use Treatment – Finding and Integral Approach	Nieves Martínez-Luna , Begoña Gonzalvo, Rebeca Ortega
987	107	Outreach towards IDUs has not been effective, finding the alternative An Indonesian case study	Budi Rissetyabudi , Sari Aznur, Laura Nevendorff
997	108	Awareness Of Predictors Of Substance Abuse	Suriaraja Guvindan Raju , Sabbitan Balakrishnan, Kavirani Nadarajan Money

"RESEARCH" POSTER SESSION (WEDNESDAY, 6TH APRIL)

ID	Board Number	Title	Authors
1011	109	Impact assessment of Life Skills Training on MMT clients	Nasim Abolghasemi, Mitra Shirazi, Mehri Nuri
1014	110	Impact assessment of CBT on relapse prevention in patients on MMT	Nasim Abolghasemi, Mitra Shirazi, Mehri Nuri
1024	111	Best Practices handbook for the setting up of a Drug Consumption Room	Alessandro Bua, María Del Río
1026	112	Evaluation of the Drug Consumption Room of Bilbao: 2003–2009	Elena Rodríguez, Unai Martín, Amaia Bacigalupe
1046	113	The report of an evaluation of HIV Prevention Harm Reduction Models in 5 Provinces in Vietnam	Nguyen Minh Tam, Trinh Huu Vach, Nguyen Thanh Long
1071	114	Perceived causes of initial decision to take drug among female drug treatment seekers at Lorestan province, Iran	Mehrdad Hosseinpour, Alireza Noroozi, Seyyed Ali Shafiee
1075	115	A survey of the results of methadone maintenance therapy in Iran Prisons in the viewpoint of physicians and consultants and experts working on health centers in prisons; a qualitative study	Mohammad Shahbazi, Ghobad Moradi, Marziyeh Farnia
1087	116	Democratizing Drug Treatment: reconsidering authority, sociality and service delivery in substitution treatment	Richard Elovich
1101	117	Young injecting drug users needs and vulnerabilities in Dar es Salaam, Tanzania	Sheryl McCurdy, Jessie Mbwambo, Daniel Maro
1110	118	Illicit drugs and drug offences – new challenges and developments for European criminal law politics	Karin Bruckmüller, Richard Soyer
1139	119	The potential of "raw" output from analytical techniques to enhance harm reduction advice to users of crack cocaine	Mohammad Zaher Shehab, Michael Rowan, Ian Blagbrough
1158	120	Perspective observational study to assess the efficacy and tolerability of Methadone, in heroin addicted patients undergoing a methadone maintenance treatment. Study METODO	Eleonora Cirri, Fausto D'Egidio, Alfio Lucchini
1160	121	The social & economic impact of drug use on families: A qualitative insight	Zainab Fazil

